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Poxviruses are a group of large double-stranded DNA virus that replicate in
the cytoplasm of the cell.  The Orthopoxvirus genus includes variola virus, the
etiological agent of smallpox, and vaccinia virus (VACV), the prototypical member
of the genus.   Cells infected with VACV display very little cell-cell fusion, however
VACV mutants deleted for either the A56R or K2L gene display extensive cell-cell
fusion.  A56 and K2 interact with one another (A56/K2) and expression of both
proteins is important for preventing cell fusion. VACV entry and fusion requires a
multiprotein entry fusion complex (EFC) composed of at least eight proteins.  In the
absence of a functional EFC infected cell fusion does not occur even when the viruses
lack either A56 or K2.  A panel of recombinant VACVs was used to define protein
interaction important for regulation of cell fusion.  Affinity purification of A56, K2
and the EFC revealed an interaction between A56/K2 and the EFC.  This interaction
required expression of both A56 and K2 as A56 did not bind the EFC in the absence
of K2 and vice versa.   Interestingly, the ability to bind the EFC correlated with the
inhibition of infected cell fusion by A56 and K2. Although the EFC contains eight
proteins, only two entry proteins, A16 and G9, were important for binding A56/K2.
Individually, A16 and G9 did not bind A56/K2; instead both A16 and G9 were
needed for efficient interaction with A56/K2.  A16 and G9 copurified with one
another when expressed by transfection in uninfected cells, confirming that the two
proteins bind to one another suggesting they directly interact within the EFC.  To
support a biological role for A56/K2 binding the EFC, cells expressing A56 and K2
were tested for infectivity as well as their ability to undergo cell-cell fusion.  In both
cases, cells expressing A56 and K2, but not individual expression of A56 or K2,
showed reduced cell-cell fusion and virus entry.  Collectively, these data support a
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Chapter 1:  Review of literature
1.1 The Poxviridae
1.1.1 Classification.
Poxviruses are among the largest animal viruses.  They have a characteristic
brick-shaped virus particle that contains the virus genome along with all of the viral
enzymes and factors required for early RNA synthesis.  Poxviruses are unusual
among DNA viruses, replicating entirely within the cytoplasm.  The family
Poxv i r idae  is divided into two subfamilies: Chordopoxvirinae and the
Entomopoxvirinae based on their respective vertebrate and insect host range.  The
chordopoxviruses have been more intensely studied than entomopoxvirues due in part
to their ability to infect humans and domesticated animals.  There are eight genera
within the Chorodopoxvirinae:  Orthopoxvirus, Parapoxvirus, Avipoxvirus,
Capripoxvirus, Leporipoxvirus, Suipoxvirus, Molluscipoxvirus, and Yatapoxvirus.
Viruses within the Orthopoxvirus genus are primarily responsible for infection of
humans, with the most notable members of the genus including variola virus
(VARV), the etiological agent of smallpox, and vaccinia virus (VACV), which was
utilized successfully as a vaccine in the eradication of smallpox.  VACV is the
prototype of the Orthopoxvirus genus and has been intensively studied in the
laboratory. Many of the poxviruses within the Chordopoxvirinae exhibit a narrow
host range and infect only a single species, although occasionally the viruses will
infect humans by zoonosis.  VARV and molluscum contagiosum virus
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(Molluscipoxvirus genus) are obligate human pathogens with no known animal
reservoir.
1.1.2 Smallpox, Edward Jenner and Vaccinia virus.
Smallpox is estimated to have evolved around 10000 BCE, about the same
time as the first agriculture settlement [1].  The disease ravaged the human population
and spared no class from its effects as evident from the skin lesions found on
mummified bodies of Egyptian pharaohs.
Prior to the advent of vaccination, the practice of “variolation” was introduced
in India and China around 1000 years ago as a strategy to prevent infection with the
smallpox virus [1].  Variolation involved the use of a small amount of infectious
material obtained from the smallpox lesion or scab.  This infectious material was used
to inoculate an individual in the hope of developing a milder form of the disease.
Variolation was born from the observation that once individuals infected with
smallpox had recovered they were protected from subsequent infection with the virus.
Variolation, possessed a significant risk to the individual by modern standards,
associated with a low mortality rate which may have in part been due to an inability
to control the inoculating dose.
It was the English physician Edward Jenner in the late 18 
th
 century who
introduced the concept of vaccination [2].  Edward Jenner observed that local
milkmaids infected with cowpox virus failed to be infected by VARV.  Jenner’s
observation led him to inoculate James Phipps with cowpox virus and later challenge
the boy with VARV.  The prior infection with cowpox virus effectively prevented the
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child from developing smallpox and changed the course of modern medicine leading
to the eventual eradication of the disease nearly 200 years later.
1.1.3 Genome organization.
The poxvirus family is divided into two subfamilies: viruses that infect
vertebrate hosts (Chordopoxvirinae) and viruses that infect insect hosts
(Entomopoxvirinae) [3].  The chordopoxviruses have a dsDNA genome of variable
length that ranges from 260 kbps for fowlpoxvirus to 140 kbps for Orf virus.  The
nucleotide composition of the chordopoxvirus genomes is quite diverse and ranges
from 64% G/C in Parapoxvirus to 33% G/C for Yatapoxvirus [3].  Despite the
variation in size and nucleotide composition, poxviruses share a common genome
organization.  The central region of the genome is conserved with respect to gene
content and arrangement.  Many of the genes located in the central region are
essential for virus replication in cell culture and have important roles in virus
transcription, replication and assembly of nascent particles.  The genome termini are
more divergent and the genes located in this region are generally not required for
virus replication in cell culture but instead function in host range and immune
evasion.  There are 90 genes conserved among the Chordopoxvirinae with most of the
conserved genes being located in the central portion of the virus genome.  Inclusion
of the entomopoxviruses reduces the number of conserved gene to 49 [4].
Vaccinia is the prototypical member of the poxvirus family.  Many of the
conserved poxvirus genes have been investigated in the laboratory by examination of
VACV.  VACV has a linear dsDNA genome of 190 kbps with covalently closed
hairpin termini [5].  Prior to sequencing of the genome of VACV it was characterized
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by digestion with restriction endonuclease HindIII.  The common VACV laboratory
strain Western Reserve (WR) contains 15 HindIII fragments designated A to O based
on their mobility in an agarose gel, with the A fragment being the largest and O the
smallest [6, 7].  VACV genes are named according to their location, position, and
direction of transcription within the HindIII fragments.  For example, A56R is the
56
th
 gene within the A HindIII fragment and is transcribed to the right as indicated by
the R.  Meanwhile, K2L is the second gene of the K HindIII fragment and transcribed
to the left.  It is common to refer to the gene with the L and R designation, while the
L and R are omitted when referring to the protein (Figure 1-1).
The ends of the VACV genome are located within the B and C HindIII
fragments and consist of 10 kbps of inverted repeat DNA [8, 9].  The sequence of the
inverted repeats consists of a total of 30 DNA repeats, with each repeat being 70 bps
in length [10].  There is significant diversity in the number of repeats between strains
of VACV.  The virus genome terminates with a conserved A/T rich region of 104 bps
to form a covalently closed hairpin [11].  The terminal portion of the virus genome,
encompassing the viral hairpin, which have been suggested to have several important
functions including initiation of DNA replication and resolution of the viral genome
concatemers [12-15].
1.1.4 Virion Morphology and Infectious particles.
Cells infected with VACV produce three morphologically distinct virus
particles: mature virus (MV), wrapped virus (WV) and extracellular virus (EV).  The
MV particle is the simplest and most abundant.  Most MV particles remain
5
Figure 1-1:  Vaccinia virus genome organization.  Diagram representing the DNA
fragments generated by digestion of the VACV genome with the HindIII restriction
endonuclease.  The DNA fragments are lettered according to their size; A is the
largest fragment, while P is the smallest.  Viral genes are named according to their
location and position within the HindIII fragment with L or R indicates the direction
of transcription.  Shown are two examples: K2 is the second gene of the K fragment
and transcribed to the left.  A56 is the 56
th
 gene of the A fragment and transcribed to
the right.
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intracellular until cell lysis but a portion acquires two additional membranes of the
trans-Golgi or endosomal origin to form WV [16].   The WV is transported to the cell
periphery on microtubles and is released from the cell by exocytosis [17].  During the
release of WV the outer of the two wrapping membranes is lost to form the  EV.  The
EV particle is surrounded by one additional membrane with respect to MV.  EV is
important for virus spread in cell culture and is thought to mediate dissemination of
the virus in vivo.  The different stages of VACV lifecycle are indicated in figure 1-2.
The MV particle has been visualized by a combination of cryo-electron
tomography and atomic force microscopy [18-20].  These studies define the MV
particle as a brick shaped structure with an average dimension of 360nm X 270nm X
250 nm.  Transmission electron microscopy of thin-sectioned MV reveal the virus is
surrounded by a single lipid membrane [21, 22], although others interpret the images
differently, suggesting the MV particle is enveloped by two tightly apposed
membranes [23-25].  The virus particle contains a dumbbell shaped electron dense
core housing the viral genome with two protein lateral bodies parallel to the
biconcave core.
1.1.5 Viral Proteins.
The 190 kbps genome of VACV is predicted to encode nearly 200 proteins.
Many of these proteins are incorporated into the virus particle.  Early analysis of the
MV virus particle by 2D electrophoresis suggested the particle was comprised of
nearly 100 proteins [26, 27].  More recently three groups have reevaluated the protein
composition of the MV particle by mass spectrometry.  The number of viral proteins
7
Figure 1-2: Lifecycle of Vaccinia virus.
Virus particles  (extracellular virus (EV) or mature virus (MV) enter the cell by direct fusion at the
plasma membrane or an endocytotic pathway to release the virus core into the cytoplasm.  The virus
core contains the DNA template, viral enzymes and transcription factors required for transcription of
early viral mRNA.  The early gene products encode immunomodulatory proteins, transcription factors
and enzymes for viral DNA replication.  Disassembly of virus core occurs during early gene
expression and leads to uncoating of viral DNA and DNA replication.  Intermediate mRNA is
transcribed after DNA replication and includes transcription factors for late gene expression.  Late
mRNA encodes many of the structural proteins for nascent particle formation as well as the early
transcription factors and enzymes to be packaged into the virus core.   Virus assembly begins with the
formation of membrane crescents.  The virus crescents are filled with the viroplasm, a mixture of
viral proteins, which evolves into spherical immature virions (IV).  Genome concatemers are resolved
during late gene expression and the unit length genome is packaged into the IV.  Virus maturation is
accompanied by proteolytic processing of viral membrane and core proteins.   A double membrane of
trans-Golgi or endosomal origin leads to wrapping of a portion of the MV to form wrapped virus
(WV).  Egress of WV occurs following transport of the WV on microtubles to the plasma membrane
and the outer membrane fuses with the plasma membrane to release extracellular virus (EV).  Viral
proteins present in the WV and EV membranes are important for recruitment of cellular proteins to
form virus tipped actin tails that aid in virus spread.
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within the MV particle varied between the studies and ranged from 63 to 80 viral
proteins [28-30].  A consensus of 73 viral proteins was identified within two of the
three studies [30].  Nearly 50% of the viral proteins within the MV particle have a
role in forming the structure or assembling the MV, while the remaining proteins are
enzymes and factors important for synthesis of viral RNA.  Most of the viral proteins
packaged into the MV particle are encoded by genes located in the central conserved
region of the genome with few proteins from the more divergent genome termini [30].
Poxvirus replication occurs entirely in the cytoplasm and very few host
proteins are required for virus gene expression.  Consequentially, poxviruses have
evolved an array of proteins for synthesis, regulation and processing of its mRNA
[31].  The virus encodes a multisubunit DNA dependent RNA polymerase [32, 33], a
heterodimeric capping enzyme [34-36], and a poly (A) polymerase [37].  Viral gene
expression is coordinated by early [38, 39], intermediate [40-43] and late [44]
transcription factors, while two viral decapping enzymes: D9 [45] and D10 [46, 47]
are thought to regulate turnover of host and viral mRNA.  Formation of protein
disulfide bonds typically occurs within the oxidizing environment of the host ER, as
the reducing environment of the cytoplasm is generally thought to prevent their
formation.  Interestingly, multiple viral membrane proteins (L1, F9, A28, H2, A16,
G9 and A21) have been identified to contain intramolecular disulfide bonds.  Three
viral proteins: E10 [48], A2.5 [49] and G4 [50, 51] are required for the formation of
these intramolecular disulfide bonds.  The E10 viral protein contains a domain with a
conserved thiol active site motif C-X-X-C common to the ERV1 (Essential for
Respiration and Vegetative Growth)/ARL (Augmenter of Liver Regeneration) family
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of cellular thiol oxidoreductases [52].  Collectively, E10, A2.5 and G4 form a
cytoplasmic pathway essential for the catalysis of intramolecular disulfide bonds [53].
VACV encodes numerous immunomodulatory proteins that help the virus
evade both the innate and adaptive immune response of the host [54, 55].  During
viral gene expression dsRNA is produced, a potent trigger of the innate immune
response.  However, the virus encodes a dsRNA binding protein, E3, which is
important for the inhibition of dsRNA dependent protein kinase R [56, 57].  The
VACV C3L gene encodes a soluble complement control protein that inhibits both the
classical and alternative pathways of complement by binding C4B and C3B [58, 59].
Poxviruses also express a number of proteins that function as defective receptors for
cytokines and chemokines [60].  The terms virokines and viroceptor was coined to
describe these decoy molecules, which are important virulence factors as viruses
lacking these proteins are attenuated in vivo.
1.1.6 Recombinant techniques for the investigation of VACV.
The roles of many VACV genes have been elucidated through targeted
deletion of viral genes and examination of the resulting phenotype.  Targeted deletion
is useful for the study of virus genes that are not essential for the virus life cycle,
however alternative strategies are used to investigate the function of essential virus
genes.  Early investigation of essential viral genes relied on random mutagenesis to
generation conditional lethal viruses in which virus growth was temperature sensitive
(ts).  VACV is normally grown at 37 
O
C, however the permissive temperature for ts
viruses is typically 31
 O
C with viruses containing a ts legion being unable to grow at
an elevated temperature of 40 
O
C.  Temperature sensitive viruses were characterized
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biochemically as well as by electron microscopy and placed into complementation
groups.  Ultimately, characterization of a temperature sensitive virus relied on
identification of the defective virus gene through complementation [61].  A more
targeted approach for the development of ts viruses employs alteration of charged
amino acids to the nonpolar amino acid alanine [62, 63].
A second approach developed to characterize genes essential for the virus
lifecycle utilizes components of the E. coli lac [64] and tet [65] operons.  Control of
viral gene expression relies on integration of the lac or tet repressor into the virus
genome and constitutive expression of the repressor protein throughout the virus
lifecycle.  Virus gene expression is controlled at the level of transcription by inserting
the DNA sequence of the lac or tet operator between the virus promoter and the
initiating methionine of the protein. An inducer, isopropyl-ß-D-thiogalactopyranoside
(IPTG) for the lac operon or Doxycycline for tet operon, is added to the medium to
allow gene expression.  The inducer prevents the repressor protein from binding to its
cognate operator thereby allowing viral gene expression.  In the absence of the
inducer the repressor protein binds to the operator and stringently repress
transcription, most likely through steric hindrance.  Basically, in the presence of the
inducer, the gene is expressed, allowing the virus to grow, while in the absence of the
inducer gene expression is repressed and the virus is unable to grow.  An alternative
approach for control of virus gene expression utilizes the phage T7 RNA polymerase
along with components of the lac operon.  Instead of relying of the virus promoter for
gene expression the gene is expressed from a T7 promoter.  Expression of T7
polymerase is dependent on the addition of IPTG [66] (See Figure 1-3).
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Figure 1-3:  Diagram of inducible gene expression in vaccinia virus.
Gene expression is controlled at the level of transcription.  The lac repressor (lacI) is
expressed constitutively from a viral early/late promoter (P7.5).  Expression of the
phage T7 polymerase is regulated by the lac operator (lacO) located between the late
viral promoter (P11) and the initiating codon of the protein. GFP is expressed from
the T7 promoter (PT7), with the lac operator located between the T7 promoter and
initiating codon of GFP.  In the absence of IPTG the lac repressor binds to the
operator preventing expression of the T7 polymerase.  A second lac operator
downstream of the T7 promoter further represses transcription.  In the presence of
IPTG the lac repressor does not bind the lac operators, allow expression of T7
polymerase, which catalyzes transcription of the GFP gene.
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1.2 Virus Entry and Replication
1.2.1 Virus Attachment.
Entry and fusion of poxviruses is complicated by the existence of multiple
forms of the virus.  Most of the studies of VACV entry have focused on the MV
particle, since it is stable and easily purified.  VACV has a broad tropism in cell
culture and is able to infect many different types of cells making isolation of a
cellular receptor difficult.  VACV fails to infect human resting T cells, but does infect
activated T cells, suggesting naïve T cells lack specific cellular factors required for
virus attachment or entry that are expressed upon activation [67].  A monoclonal
antibody reactive to a cell surface antigen was isolated and shown to prevent virus
attachment, although the specificity of the antibody remains to be identified [68].
Initial attachment of the MV particle to the cell is facilitated by interactions
between the virus and cell surface glycosaminoglycans (GAGs).  Three VACV
proteins have been reported to mediate virus attachment: D8, H3 and A27.
Individually, D8 [69], H3 [70] and A27 [71, 72] are not required for virus growth in
cell culture.  This may not be all that surprising as A27, H3 and D8 proteins may have
slightly redundant function with respect to virus attachment, which would be
consistent with individual deletions of the proteins not having a more severe effect on
virus growth [73-75].  However, virus attachment is not solely dependent on GAGs as
VACV still binds and infects Sog9 cells, which lack the GAGs heparin sulfate and
chondroitin sulfate [76].  A recent report suggested that cellular laminin is an
important cellular attachment factor since soluble inhibited virus attachment in a dose
dependant manner [76].  Cholesterol within the cell membrane has also been
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demonstrated to be important for virus entry.  Depletion of cholesterol from the cell
membrane by treatment with methyl-!-cyclodextrin reduced cell infectivity by 90%.
Infectivity was restored by addition of exogenous cholesterol, indicating an important
role for cholesterol in VAV attachment/entry [77].  The cellular factors important for
virus attachment and entry remain to be fully characterized and further investigations
will likely reveal other cellular factors that play a role in this process.
1.2.2 Virus Entry.
Entry and fusion of VACV requires a conserved multiprotein complex of at
least eight proteins: A16 [78], A21 [79], A28 [80], L5 [81], G3 [82], J5, G9 [83], and
H2 [71].  The proteins of the EFC are integral membrane proteins located within the
MV membrane and critical for infectivity of the virus, although it remains to be
determined if the EFC directly mediates virus fusion.  All of the entry proteins
contain a single transmembrane anchor and the proteins fall into two groups based on
their predicted topology within the virus particle.  A28, A21, H2, G3 and L5 possess
an N terminal transmembrane domain and have 0-2 intramolecular disulfide bonds,
while A16, G9 and J5 have a C terminal transmembrane domain with 4-10
intramolecular disulfide bonds.  The cysteine rich domains of A16, G9 and J5 are
homologous, suggesting the proteins arose through gene duplication and diverged to
have independent roles in virus entry.  There is no detectable homology between A28,
A21, H2, G3 and L5.  The entry proteins have no role in assembly of the MV, WV or
EV particle.  Viruses that lack a single entry protein have been isolated and bind
normally to cells, but fail to enter indicating a block in virus entry or fusion.
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The EFC is critical for virus entry and all proteins of the complex must be
expressed for the virus to enter.  The absence of a single entry protein is sufficient to
prevent the complex from assembling, although if the complex does not form the
remaining entry proteins are still  incorporated into the MV membrane [84].  This
potentially indicates the entry proteins localize to the virus membrane prior to
forming the EFC.  In fact, the EFC does not form in the absence of the virus
membrane, which would be consistent with the entry proteins localizing to the viral
membrane prior to assembling into the complex.
Intramolecular disulfide bonds have been shown to form in the cytoplasmic
domains of several of the entry proteins: A16 [78], G9 [83], A21 [79], L5 [81] and
A28 [85].  Interestingly, repressing the E10 protein, an essential component of the
VACV cytoplasmic disulfide bond pathway, had no effect on assembly of the EFC.
Therefore disulfide bonds do not appear to be important for assembly of the complex,
however because E10 is essential for virus morphogenesis the role of disulfides bonds
in the entry of the virus has not been assessed.  With eight proteins forming the EFC
it is likely that a number of protein interaction are required for formation of the entry
complex, however these interactions remained to be defined.  In the absence of A16,
the H2 and A28 entry proteins were observe to remain associated, suggesting the two
proteins may interact within the EFC [84].
In addition to the proteins of the EFC, several other viral proteins have been
suggested to be important for MV entry.  The ability to isolate neutralizing antibodies
to the A27 and L1 proteins suggested that these two proteins might be important for
virus entry [86-88].  Analysis of the A27 protein indicated a role in the wrapping of
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MV to form WV.  Viruses lacking A27 remained infectious, indicating the A27
antibody may inhibit virus entry through steric hindrance [71, 72].  The role of the L1
protein in virus entry has not been investigated because the protein is required for
virus morphogenesis preventing isolation of virus particle deficient in L1 [89].
The L1 protein shares 20% amino acid identity with F9, suggesting these two
proteins may have had a common gene ancestor (i.e. one of the proteins arose from
gene duplication of the other).  Unlike L1, there is no block in morphogenesis in the
absence of F9 and all of the forms of the virus are produced.  Virus particles lacking
F9 bind to the cell, however their cores do not penetrate into the cytoplasm [90].  This
phenotype is identical to that observed for the proteins of the EFC.  The F9 protein
was shown to interact with proteins of the EFC, although the interaction was difficult
to detect suggested the protein may only associate with a portion of the entry
complexes.  The functional role of F9 is consistent with its interaction with the EFC,
although the significance of the interaction remains to be determined.
The MV particle of VACV has been shown by EM to fuse at the cell surface
[91-93].  Virus particles are also observed in intracellular vesicles suggesting entry
through an endocytic route [94, 95].  Several recent studies investigating MV entry
have used a recombinant VACV that expresses the firefly luciferase under the control
of an early viral promoter [94].  Luciferase (Luc) expression, which can be detected
as early as 30 minutes postinfection, is measured and used to quantify virus entry.
MV bound to the cell surface and exposed to low pH display a 10-fold increase in
Luc activity compared to an identical sample treated with neutral pH [94].  The
ability of low pH to influence virus entry is consistent with entry through an
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endocytic route, with low pH treatment mimicking the pH reduction that occurs
within the endosome.  Inhibitors of endosomal acidification decrease entry of MV
particles by 60-80% depending upon the cell type [94].  The effect of inhibiting
endosomal acidification can be particularly rescued by treating the virus bound to the
cell surface with low pH.  The low pH presumably triggers fusion of the particle with
the cell surface thereby bypassing the requirement of the low pH within the
endosome.
While most of the studies on the entry of VACV have focused on the MV
particle, few studies have looked at EV.  Entry of the EV, which contains one
additional membrane with respect to the MV particle, is difficult as the EV membrane
is fragile and prone to damage during purification.  EV was proposed to enter by
endocytosis, with the low pH environment of the endosome disrupting the EV
membrane [96].  Recently EV has been shown to enter the cell by directly fusion with
the plasma membrane.  The EV membrane is disrupted by soluble GAGs, to release
the MV particle [97].  The EV membrane serves as an accessory during entry of EV
with virus-cell fusion depending on the EFC in the MV membrane.
1.2.3 Virus gene expression.
Virus entry is followed by release of the virus core into the cytoplasm.  The
core is transported on microtubules to a perinuclear site within the cytoplasm [98].
Disassembly of the core, which releases the virus genome into the cytoplasm, requires
early gene products and is prevented by protein synthesis inhibitors [99].  The virus
core contains all of the enzymes and factors required for viral transcription and early
viral mRNA synthesis occurs independent of de novo protein synthesis.  The
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transcriptional apparatus of VACV has been extensively characterized by isolating
the enzymes present within the virus core.  An extract from the virus core is able to
synthesize RNA in vitro and the resulting mRNA is capped at its 5’ end and contains
a 3’ poly(A) tail [100].
Virus genes are divided into prereplicative and postreplicative classes
depending on whether they are expressed before or after viral DNA replication.  Early
viral gene expression occurs prior to DNA replication, while intermediate and late
gene expression occur after viral DNA replication.  Class specific promoters and
transcription factors coordinate expression from each class.  Early transcription
factors are the products of late viral genes that are packaged into the virus particle
during the previous infectious cycle.  Early viral gene expression occurs shortly after
the virus enters into the cytoplasm with RNA/DNA hybridization studies suggesting
nearly 50% of the genome is transcribed during this early phase [101, 102].
Intermediate transcription factors are the products of early genes, however
intermediate transcription is delayed until after viral DNA replication.  Inhibitors of
viral DNA replication block intermediate transcription [44].  Interestingly, an
intermediate promoter transfected into virally infected cells is transcribed even under
conditions in which viral DNA replication is inhibited.  This suggests the template for
intermediate gene expression is not accessible until after DNA replication, likely
indicating the newly replicated DNA serves as the template [44].  Intermediate
transcription in vitro requires three viral factors: viral intermediate transcription factor
(VITF) VITF-1, VITF-2 [41], and VITF-3.  The E4L gene encodes VITF-1 [40],
while VITF-3 is a heterodimer of A8R and A23R [43].  In contrast, VITF-2 is a
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heterodimer of two cellular proteins: Ras-GTPase-activating protein SH3 domain-
binding protein (G3BP) and p137 [103].  Both G3BP and p137 are found in distinct
regions of the viral factory along with the intermediate transcription factor A23R.
G3BP, p137 and A23R localized to similar regions of the viral factories as viral
mRNA and two translation initiation factors: eIF4E and eIF4G.  These findings
suggest virus transcription and translation is coordinated within the virus factory
[104].
The viral late transcription factors are the products of intermediate genes.
Three viral proteins are required for the transition from intermediate to late gene
expression: A1 [105], A2 [106] and G8 [107].  In vitro, the H5 protein has been
shown to enhance late viral gene transcription [108].  Late gene expression continues
until the cellular resources are depleted or cell lysis occurs.
VACV early, intermediate and late gene promoters are located immediately
upstream of viral genes.  The poxvirus promoters are conserved, with the promoter
from one type of poxvirus functioning within cells infected with a different poxvirus.
The features of both early and late VACV promoters have been characterized by
single nucleotide substitution.  Early promoters contain an A+T rich core sequence
between  –13 and –28, followed by a spacer region of 12 nucleotides and initiation of
transcription starting with an A or G nucleotide (Note: +1 is the transcription start
site) [109].  Late promoters contain a highly conserved TAAAT sequence with
transcription initiating within the A triplet of TAAAT [110].  The TAAAT is
commonly followed by a G nucleotide to form TAAATG, with ATG serving as the
initiating codon for protein synthesis.  Intermediate promoters contain an important
19
core region from –26 to –13 and have a conserved sequence TAAA, with
transcription initiating within the A triplet [111].  The 5’ of intermediate and late
mRNA contains a poly(A) leader of 30-40 bps [112, 113].  The poly(A) leader may
arise as a consequence of the polymerase stuttering within the AAA found in both
intermediate (TAAA) and late promoters (TAAAT).  Although the poly(A) leader is
generally absent from early mRNA, several early promoters contain a TAAAT
sequence and analysis of the 5’ end revealed a poly A tract, although the length of the
leader was reduced to only 15-20 bps [114].  The significance of the 5’ poly(A) leader
is unknown, but it may have a role in enhancing translation of the mRNA.
The length of the mRNA transcript varies depending on the transcription
class.  Early transcripts have a defined length resulting from transcription termination
downstream of the sequence TTTTTNT, where N is any nucleotide including T [115].
The termination sequence is recognized within the nascent mRNA transcript [116]
and transcription ends 20-50 bps after the sequence.  Intermediate and late mRNA
lack defined termination signals resulting in mRNA of heterogeneous length [117,
118].  Several late viral mRNAs undergo cleavage at their 3’ UTR [119]. The activity
responsible for in vitro cleavage of the 3’ UTR copurified with the H5 protein.
However, a recombinant H5 protein expressed in E. coli was unable to cleave the
3’UTR suggesting there may be additional factors important for cleavage [120].
1.2.4 Genome replication.
VACV encodes most, if not all, of the proteins required for replication of its
genome.  Enucleated cells support replication of the virus, albeit at a reduced rate
[121, 122].  VACV infected cells form discrete cytoplasmic bodies known as “viral
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factories” that localize adjacent to the nucleus and stain densely with fluorescent
DNA dyes.  The viral proteins important for DNA replication are synthesized from
early genes and viral replication begins within 1 to 2 h postinfection.  The viral
proteins important for DNA replication include, but are not limited to, the DNA
polymerase (E9) [123], uracil DNA glycosylase (D4) [124], the protein kinase (B1)
[125, 126], nucleic acid-independent nucleoside triphosphatase (D5) [127, 128], and a
viral DNA processivity factor (A20) [62, 129].  The B1 kinase phosphorylates the
cellular protein barrier to auto integration factor (BAF) [130].  BAF is suggested to
bind to the viral DNA and inhibit its replication.  B1 phosphorylation of BAF is
thought to prevent the protein from binding the viral DNA, although the exact
mechanism by which BAF inhibits DNA replication is unknown [131].  The viral D5
protein shares limited homology with the archaeoeukaryotic primase superfamily
[132] and purified recombinant D5 protein was shown to catalyze oligoribonucleotide
synthesis consistent with a role as a primase [133].  The D4 and A20 proteins interact
and are important for processivity of the viral DNA polymerase in vitro [134].
The mechanism of VACV DNA replication is poorly characterized.  Attempts
to identify a viral origin of replication were unsuccessful and instead showed the
virus is able to replicate plasmid DNA devoid of any viral genomic DNA [135].
Plasmid DNA is thought to replicate by a rolling circle mechanism within the viral
factory and was shown to depend on the same viral proteins essential for genome
replication [136].  The current model of VACV DNA replication hypothesizes that
the viral DNA replicates by a rolling hairpin mechanism, with nicking of the virus
genome within hairpin termini serving as a primer for DNA replication.  The
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replication of both the viral genome and plasmid DNA results in long DNA
concatemers (i.e. direct repeats of the genomic DNA).  An A/T rich DNA sequence
located near the hairpin termini of the viral genome is important for resolution of the
plasmid DNA concatemers [137].  This sequence is conserved amongst poxvirus,
suggesting an important role in resolution of viral genome concatemers.  Resolution
of the viral concatemers requires the action of a late viral gene product encoding a
holiday junction resolvase (A22) [138]. The purified A22 protein resolves synthetic
holiday junctions in vitro and repression of the A22 gene prevents resolution of
genome concatemers [139, 140].  Following DNA replication, the virus transition to
intermediate and late gene expression in which the replicate viral genome is packaged
into the nascent virus particle.
1.2.5 MV morphogenesis.
Assembly of VACV occurs within cytoplasmic viral factories.  The various
stages of MV morphogenesis have been defined by electron microscopy.  The first
structures of virus morphogenesis observed by electron microscopy are membrane
crescents, although the cellular organelle from which the membrane crescents are
formed remains controversial.  Some studies propose the membrane is synthesized de
novo [22] or originates from the ER/Golgi intermediate compartment [25], while
more recent evidence favors the idea that the membrane crescents are derived from
the ER membrane [141].  Formation of membrane crescents does not occur in the
absence of the viral proteins F10 [142], A11 [143], H5 [144] or G5 [63].  Membrane
crescents associate with an electron dense granular viroplasm containing viral
proteins destined for the viral core.  Association of membrane crescents with the
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viroplasm requires a complex of seven proteins: F10, A30, G7, J1, D2, D3 and A15
[145].
Membrane crescents evolve into spherical immature virus (IV) particles.  The
transition from membrane crescent to IV is inhibited by the antibiotic rifampicin.
Viral mutants resistant to rifampicin have been isolated and the mutations map to the
D13L gene [146].  D13 forms a honeycomb lattice around the IV, but is not packaged
into the MV particle.  Instead, D13 may serve as a scaffold for the assembly of IV
[147].  The viral genome is packaged into the virus core at the IV stage.  Two viral
proteins, A32 [148] and I6 [149], have been shown to be important for encapsidation
of the viral genome.
The transition from IV to MV is poorly defined, but is associated with the
proteolytic cleavage of viral membrane and core proteins.  VACV has two predicted
proteases encoded by G1L and I7L.  G1L is a predicted metalloprotease with an
essential role in the transition from IV to infectious MV [150], however G1 is not
required for cleavage of the viral core proteins.  The I7 protein shares homology with
other known cysteine proteases and is responsible for cleavage of the viral core
proteins A3, A10 and L4 as well as the viral membrane protein A17 [151].  There are
several other proteins, including A12 and G7, which also undergo proteolysis.  The I7
protease recognizes a consensus AG/X motif [(/) denotes site of cleavage], however
other undefined factors influence substrate specificity.  For example, the F10 protein
contains an AG/X motif, yet does not appear to be cleaved.  When synthesis of I7 is
repressed, cleavage of the viral core and membrane proteins does not occur and
noninfectious irregular virus particles containing an aberrant core structure are
formed.
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1.2.6 Formation of Wrapped and Extracellular virus.
There are at least eight viral proteins that localize to either the EV or the WV
membrane: A33, B5, A34, A56, K2, and F13 are found in the EV membrane, while
A36 and F12 specifically localize to the WV membrane.  Wrapping of MV is
severely compromised in the absence of the EV proteins F13 [152] and B5 [153, 154]
as well as the MV protein A27 [155]. WV are transported to the periphery of the cell
on microtubles [156].  In the absence of A36, WV transport is impaired, suggesting a
role for this protein in WV transport [157].  This was supported by yeast two hybrid
screening which identified an interaction between A36 and the light chain of the
microtubule motor protein kinesin [158].  A more severe defect in WV transport was
noted in the absence of F12, indicating A36 is not solely responsible for transport of
WV to the cell surface [159].  Upon reaching the cell surface the WV particle
undergoes exocytosis and loses one of the two wrapping membranes to form EV.
The virus recruits cellular machinery to form virus tipped actin tails important
for spread of the virus [160].  In the absence of actin tails, the virus forms small
plaques, indicating an important role for actin tails in virus-cell spread.  Actin tail
formation requires multiple WV and EV proteins including A36 [161], A33 [162] and
A34 [163].  Phosphorylation of two tyrosine residues within A36 is critical for the
recruitment of the cellular proteins required for actin tail formation [164].
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1.3 Virus Fusion and Regulation of Infected Cell Fusion
1.3.1 Low pH induced cell-cell fusion.
During a typical VACV infection there is very little fusion between infected
cells, however a brief exposure to a pH below 6 induces extensive cell-cell fusion.
There are two forms of low pH cell fusion: i) fusion from without and ii) fusion from
within.  Fusion from without requires adsorption of a large amounts of purified virus
(MOI 300-500) to the cell surface [165, 166]. Fusion from within occurs at late times
during infection and requires cell surface EV [72, 152].  Following exposure to low
pH, cell fusion develops over several hours, while a similar treatment with neutral pH
fails to trigger cell fusion.  The ability of VACV to induce cell fusion following low
pH is characteristic of viruses that enter through a low pH endocytic route, with low
pH mimicking the pH drop in the endosome and stimulating virus fusion at the
plasma membrane instead of the endosome.  It is thought that low pH activates the
virus entry machinery and triggers fusion of the virus membrane with the plasma
membrane.  Consequentially, the viral proteins formally in the viral membrane are
relocated to the cell membrane positioning the EFC to mediate fusion with adjacent
cells, eventually forming large multinucleated syncytia (Figure 1-4).  Neutralizing
antibodies are able to inhibit the development of low pH cell-cell fusion consistent
with the process of cell-cell fusion being closely related to virus cell fusion [86-88].
More recently VACV entry has been shown to require a multiprotein EFC, although it
is uncertain
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Figure 1-4: Model of VACV induced low pH cell-cell fusion.
(Fusion from without.)  A large number of mature virus (MV) particles is bound to
the surface of an uninfected cell and then treated briefly with low pH (5.5 or below)
medium.  Low pH synchronizes MV fusion with the plasma membrane and deposits
the viral membrane with the entry fusion complex (EFC) into the cell membrane.
The EFC within the cell  membrane mediates fusion between adjacent cell leading to
formation of multinucleated syncytia.  (Fusion from within.)  Cells infected with
VACV possess surface extracellular virus (EV).  Following treatment with low pH
medium the EV membrane ruptures to expose the MV particle, which fuses with the
cell membrane.
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whether the EFC directly mediates fusion or instead is important for assembly of the
viral fusion apparatus.  Never the less, the EFC is required to mediate all forms of low
pH cell fusion.
1.3.2 A56R and K2L.
In addition to low pH cell fusion described above, VACV triggers neutral pH
cell fusion when either the VACV A56R [167] or K2L [168-170] gene is absent.  A56
is known as the viral hemagglutinin for its ability to agglutinate red blood cells of
certain species.  K2 is one of three viral proteins with homology to serine protease
inhibitors (SERPINS) and has been referred to as serine protease inhibitor 3 (SPI-3),
[171].  Tissue culture cells infected with closely related cowpox virus with deletions
of the cowpoxvirus HA (VACV A56R homologue) or SPI-3 of cow pox (VACV K2L
homologue) also develop extensive cell-cell fusion.  Neutral pH cell fusion is induced
by specific monoclonal antibodies that react with A56 [172] or K2 [173].  The
mechanism by which the A56 and K2 antibodies trigger cell fusion is unknown,
although the antibodies may perturb protein interactions of A56 or K2 required for
inhibition of cell fusion.  Neutralizing antibodies (which normally prevent virus
infection) added to cultures following infection with VACV lacking A56 or K2
inhibit neutral pH cell fusion [169].  Neutral pH cell fusion depends on EV, which is
also required for low pH fusion from within, suggesting the two forms of fusion occur
by a similar mechanism [152].
Both A56 and K2 localize to the plasma membrane of infected cells and are
incorporated into the membrane of EV [174].  K2 binds to A56 and this interaction is
required for proper localization of K2 [173].  K2 lacks a membrane anchor and is
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secreted from infected cells in the absence of A56.  The K2 protein is glycosylated,
however point mutations that abolish the four putative N linked glycosylation sites
have no effect on the ability of K2 to inhibit cell-cell fusion [174].  A56 possesses
both N and O-linked glycosylation [175], but the role of glycosylation in the anti-
fusion activity of A56 has not been studied.  Although A56 is an integral membrane
protein in the EV particle, the protein has no role in formation of EV and the virus is
able to form virus tipped actin tails in the absence of A56 or K2.  Immunoelectron
microscopy reveals that A56 is inconsistently incorporated into the EV membranes
with approximately one third of EV particles lacking A56, although the significance
of this is unknown [176].  Deletion of A56 caused a slight attenuation of disease in an
intranasal mouse model [177], while no effect on viral virulence was observed when
K2 was deleted [168].  Recombinant K2 was shown to function as a SERPIN in vitro
[178].  The cowpox SPI-3 and myoxoma SERP1 both exhibit similar proteinase
inhibition profiles in vitro, however the myoxoma SERP1 is unable to complement
the anti-fusion activity of SPI-3 [179].  This result may have been predicted as it was
shown earlier that point mutations that abolish the SERPIN activity of the cowpox
SPI-3 (VACV K2L homologue) in vitro have no effect on the anti-fusion activity of
the protein [180].
The mechanism by which A56 and K2 regulate cell-cell fusion is poorly
understood.  Curiously, cell-cell fusion only occurs among infected cells that are
deficient for A56.  This was established by infecting cells with an A56 deletion virus
and a separate cell population with wild-type virus that expressing A56.  The infected
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cells were mixed and cell fusion was noted to occur only among hemagglutination
negative cells [167].
The deletion of A56 and K2 causes neutral pH cell fusion which is thought to
develop as a result of reinfection by cell surface EV.  There are several stages at
which A56 and K2 could prevent EV reinfection.  Entry of EV depends on expression
of the EFC within the MV membrane and is only exposed upon rupturing of the EV
membrane.  Since both A56 and K2 are found in the EV membrane the proteins could
stabilize the membrane to prevent premature rupturing.  However, since the EV
membrane appears to be quite fragile even in the presence of A56 and presumably K2
[181] inhibition of fusion is probably due to an alternative mechanism.  Both A56 and
K2 are abundant in the plasma membrane of infected cells and there is evidence to
suggest this localization is important as cell fusion develops with (i) monoclonal
antibodies to A56 [172] or SPI-3 [173] or when (ii) the membrane anchor of HA is
removed [173] or (iii) the signal sequence of SPI-3 is removed [174].  This thesis will
define the protein interactions of VACV A56R and K2L with the aim of elucidating a
mechanism by which these proteins regulate infected cell fusion.
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Chapter 2: The VACV A56R and K2L associate with proteins of the
Multicomponent Entry/Fusion Complex
2.1 Introduction
VACV is the prototypical member of the Orthopoxvirus genus.  Poxviruses
are large DNA viruses with a brick shaped virus particle [3].  VACV replicates in the
cytoplasm of the cell and produces several types of infectious particles, the simplest
of which is MV. The MV particle is surrounded by a lipid membrane that contains
nearly 20 viral membrane proteins [182].  The virus core houses the viral genome
along with all of the enzymes and factors necessary for early RNA synthesis.  The
MV particle remains intracellular until lysis, however a portion of MV acquires a
double membrane derived from modified trans-Golgi or endosomal cisternae to form
WV [16], which is transported on microtubles to the cell surface and released by
exocytosis [183].  The resulting EV particle is essentially an MV with one additional
membrane.
Entry of the MV particle has been shown to occur by fusion with the plasma
membrane [91], while entry is also enhanced by briefly lowering the pH of the
medium below 6, characteristics of entry through a low pH endocytic route [94].
Chemical inhibitors of endosome acidification reduce MV entry by 80%, but can be
partially rescued by treatment with low pH [94].  Low pH treatment of infected cells
triggers cell-cell fusion [152, 165, 166].  Cell fusion also occurs spontaneously at
neutral pH when cells are infected with VACV or the closely related cowpox virus in
which the A56R gene encoding the viral hemagglutinin (HA) [167] or K2L encoding
a serine protease inhibitor (SPI-3) [168, 169, 170] is mutated or deleted.  The A56R
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gene of VACV is a type-I membrane protein that localizes to the EV and plasma
membrane [172, 184].  The K2L gene (SPI-3) does not contain a membrane anchor
and associates with the EV and plasma membrane through an interaction with A56R
[173, 174].  The anti-fusion activity requires both proteins to localize to the cell
membrane.  This is supported by the following evidence as syncytia form when (i)
poxvirus-infected cells are incubated with antibodies to HA [172] or SPI-3 [173], (ii)
the membrane anchor is removed from HA [173] or (iii) the signal sequence of SPI-3
is removed [174].  A56 possess no putative catalytic motifs and the serine protease
inhibitory activity of SPI-3 is not required for fusion inhibition [180].
Virus-cell fusion and low pH-induced cell-cell fusion requires the same EFC
found in the MV membrane, which consists of at least the following eight viral
proteins: A16, A21, A28, G3, G9, H2, J5 and L5 [84, 94]. The study described in this
chapter investigates the role of the EFC in neutral pH cell fusion associated with
deletion of A56R or K2L gene. Furthermore, tandem affinity purification is utilized to
determine the protein interaction of A56 and K2 which may be important for their
anti-fusion activity.  This study has been previously described in reference [185]
2.2 Materials and Methods
2.2.1 Cell and virus propagation.
BS-C-1 (ATCC CCL-26) and RK13 (ATCC CCL-37) cells were grown in
Minimum Essential Medium with Earle’s balanced salt supplement (EMEM; Quality
Biologicals, Gaithersburg, MD) containing 2 mM L-glutamine, 10% fetal bovine
serum (FBS), penicillin and streptomycin. HeLa S3 (ATCC CCL-2.2) suspension
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cells were cultured in Minimum Essential Medium, Spinner modification (Quality
Biologicals) with 5% equine serum and L-glutamine.   Unless specified, all
recombinant viruses were derived from the Western Reserve (WR) strain (ATCC VR-
1354; accession number AY243312). Virus stocks were prepared as described [186].
Viral titers were determined by plaque assay using a confluent monolayer of BS-C-1
grown in six-well cluster plate.   A 10-fold serial dilution of virus stocks was prepared
in EMEM containing 2.5% FBS, glutamine and antibiotics (2.5% EMEM).  Medium
was removed from the six-well plate and 0.5ml of serially-diluted virus inoculum was
incubated 1 h at 37 
o
C and 5% CO2.  The cells were then overlaid with 2.5% EMEM
containing 0.5% methylcellulose and incubated 48 h.  The plaques were visualized by
staining with 0.1% crystal violet (w/v) in a solution of 20% ethanol and deionized
water.
2.2.2 TAP and mass spectrometry.
HeLa S3 cells (1.5 x10
9
) were infected at a multiplicity of 5 plaque-forming
units (PFU) and after infection for 24 h the cells were collected, washed once with
ice-cold buffer (150 mM NaCl and 50 mM Tris-HCl pH 7.4), and lysed by incubating
for 1 h at 4
o
C in streptavidin binding buffer (SBB) (1% Triton X-100, 150 mM NaCl,
50 mM Tris-HCl pH 7.4) with complete protease inhibitor (Roche, Indianapolis, IN).
The lysate was centrifuged for 15 min at 3000 X g and the clarified supernatant was
collected. The latter, except for 0.3 ml reserved for later analysis, was added to 0.5 ml
to 1 ml of streptavidin sepharose (GE Healthcare, Piscataway, NJ) that had been
washed with SBB and the mixture rotated overnight at 4oC.  The beads were washed
3 times with 10 ml of ice cold SBB and the bound proteins eluted by 3 washes with 1
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ml of SBB containing 1mg/ml of D-Biotin (USB corporation; Cleveland, OH).  The 3
ml of streptavidin eluate was supplemented with Mg acetate, imidazole, and CaCl2 to
final concentrations of 1 mM, 1 mM and 2 mM, respectively.  Calmodulin Sepharose
(0.5 ml to 1 ml of packed resin; GE Healthcare) was washed with calmodulin binding
buffer (CBB; which consists of SBB supplemented with Mg acetate, imidazole and
CaCl2 at final concentrations of 1 mM, 1 mM and, 2 mM, respectively).  Calmodulin
Sepharose was added to the supplemented streptavidin eluate along with an additional
2 ml of CBB and the mixture rotated overnight at 4
o
C. The beads were washed 3
times with 10 ml of CBB and 3 times with 0.75ml of SBB containing 25 mM 2-[2-[2-
[2-[bis(carboxymethyl)amino]ethoxy]ethoxy]ethyl-(carboxymethyl)amino]acetic acid
(EGTA) to elute proteins.  The proteins in the calmodulin eluate were concentrated by
trichloroacetic acid precipitation and then resuspended in lithium-dodecyl sulfate
(LDS) sample buffer (Invitrogen, Carlsbad, CA) containing NuPage sample reducing
agent (Invitrogen) and separated on a 4-12% NuPage gel (Invitrogen) with 2(N-
morpholino)ethanesulfonic acid buffer.  Gels were stained with Coomassie blue
(GelCode blue stain Reagent, Pierce, Rockford, IL) and bands of interest were
excised from the polyacrylamide gel and subsequently digested with trypsin.  Tandem
mass spectrometry and database searching were performed at the National Institute of
Allergy and Infectious Diseases core facility.
2.2.3 Recombinant virus construction.
The following recombinant viruses were constructed for this study (Table 2-
1): vK2TAP, vA28TAP, and vA56TAP vA28i"A56 vA28i"K2 v"A56 and
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vK2TAP"A56 v"A56"K2, vA56TAP"K2 and vA28TAP"K2, vsA56TAPi,
vK2i"A56, vsA56TAPi"C3, vT7lacOI"F13
vK2TAP, vA28TAP, and vA56TAP were constructed using DNA encoding
(i) K2L, A28L or A56R genes with 300 bps of downstream flanking region, (ii)  the
TAP tag derived from pCTAP (Stratagene, La Jolla, CA), and (iii) a strong VACV
promoter adjacent to the gene for a fluorescent protein namely Heteractis crispa red
fluorescent protein 1 (HcRed) from Clontech (Mountain View, CA) for K2TAP and
enhanced green fluorescent protein (EGFP) from Clontech for A28TAP.  The
constructs were prepared by overlapping PCR (Accuprime Pfx, Invitrogen, Carlsbad,
CA) so that the TAP tag sequence was appended immediately before the stop codon
of the modified gene.  The gene encoding the fluorescent reporter was inserted
between the stop codon and the 300 bps flanking region.  The PCR product was
cloned into pCR-BluntII-TOPO (Invitrogen) and the TOPO plasmids encoding
K2TAP and A28TAP were transfected with Lipofectamine 2000 (Invitrogen) into
BS-C-1 cells that had been infected 1 h earlier with 1 PFU per cell of VACV.
Parental and recombinant viruses were distinguished by fluorescence microscopy and
three rounds of plaque isolation clonally purified the latter. vA56TAP was
constructed as above except that v"A56 was used as the parental virus and the EGFP
gene in the A56R locus was replaced with A56TAP; recombinant viruses were
distinguished from the parental virus by the absence of green fluorescence.
Deletion of the A56R and K2L genes was achieved by replacing the open
reading frames with the DNA encoding EGFP or HcRed, respectively.  Briefly, 300
bps of DNA corresponding to the left and right flanks of A56R and K2L were fused
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by recombinant PCR to the fluorescent protein gene.  To construct vA28i"A56 and
vA28i"K2, BS-C-1 cells were infected in the presence of 100 µM IPTG with vA28i
[85] at 1 PFU per cell and then transfected with the respective A56 or K2 deletion
plasmid.  Recombinant viruses were distinguished from parental virus by
fluorescence microscopy and clonally purified by three rounds of plaque isolation.
v"A56 and vK2TAP"A56 were constructed by deletion of the A56R gene from
VACV strain WR and vK2TAP, respectively, utilizing an approach analogous to that
described for vA28i"A56.  The K2L gene was deleted from v"A56, vA56TAP and
vA28TAP as described for vA28i"K2 and the resulting viruses were designated
v"A56"K2, vA56TAP"K2 and vA28TAP"K2, respectively
vK2i"A56 was designed to inducibly over express an influenza HA epitope-
tagged inducible K2.  The corresponding transfer plasmid was assembled by
recombinant PCR from: (i) 200 bps of DNA upstream of the A56R gene, (ii)
bacteriophage T7 promoter and encephalomyocarditis virus leader sequence
containing an internal ribosome entry site from pVote 1 [187], (iii) K2L with a C
terminal influenza HA epitope tag sequence, (iv) HcRed gene regulated by a strong
VACV promoter, and  (v) 200 bps of DNA downstream of A56R.  The final PCR
product was cloned into PCR-BluntII-TOPO and sequenced.  The K2L expression
plasmid was transfected into cells infected with vT7lacOI [66]and the vK2i"A56
plaques were detected by fluorescence microscopy. vK2i"A56 was clonally purified
by three rounds of plaque isolation.
vsA56TAPi, a virus encoding an inducible A56 that is secreted from cells
because of deletion of its transmembrane segment and contains TAP, V5 and 10-
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histidine tags, was constructed. The virus vT7lacOI"F13 was created by first deleting
the F13L gene from vT7lacOI in order to provide subsequent plaque selection [188].
A DNA segment was assembled by overlapping PCR using DNA encoding (i) the T7
promoter, encephalomyocarditis leader sequence, and E. coli lac operator from pVote
1 to provide inducible expression and cap-independent translation, (ii) A56R gene
with a V5 tag inserted between codons 18 and 19 and replacement of codons 280 to
315 with a TAP tag sequence followed by 10 tandem copies of a histidine codon, and
(iii) T7 termination sequences from pVote 1. This DNA was then cloned into pRB21
[188] and the resulting plasmid was used to transfect BS-C-1 cells that had been
infected with vT7lacOI"F13.  The new recombinant virus vsA56TAPi formed large
plaques and was clonally purified. The C3L gene was deleted from vsA56TAPi and
vK2i"A56 in a similar fashion as described for deletion of A56 to construct
vsA56TAPi"C3 and vK2i"A56"C3, respectively.
2.2.4 Western blotting.
Samples subjected to TAP from 2-3 X 10
8  
HeLa S3 cells were separated by
loading onto a 10% or 4-12% NuPage Bis-Tris gel (Invitrogen).  Following
electrophoresis, the proteins were transferred to nitrocellulose membranes and
blocked with Tris-buffered saline supplemented with 5% nonfat dried milk and 0.05%
Tween-20 (TBST) for 1 h at room temperature.  The membranes were then incubated
with the appropriate primary antibody, washed, incubated with horseradish
peroxidase-conjugated secondary antibodies (GE healthcare, Piscataway, NJ), and
analyzed with the SuperSignal West Dura or Femto Maximum Sensitivity Substrate
chemiluminescence reagents (Pierce, Rockford, IL).
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Transmembrane and cytoplasmic tail of A56 removed and replaced with TAP-tag
Recombinant virus Parent   [Reference] Description
v"A56 VACV WR Deletion of A56R
v"A56"K2 v"A56 Deletion of A56R and K2L
vA28TAP VACV WR A28-TAP
a
vA28i"A56 vA28i              [80] Inducible A28-HA
b
; deletion of A56R
vA28i"K2 vA28i              [80] Inducible A28-HA
b
; deletion of K2L
vA28TAP"K2 vA28TAP A28-TAP
a





; deletion of K2L
vsA56TAPi vT7lacOI"F13




vK2i"A56 vT7lacOI        [66] Inducible K2-HA
b
; deletion of A56R




; Deletion of A56R
vT7lacOI"F13 vT7lacOI        [66] Inducible T7 polymerase; constitutive
expression of lac repression; deletion
of F13L
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Primary and secondary antibodies were removed from the membrane by




Rabbit polyclonal antisera used to detect VACV proteins were: anti-A21 [79],
anti-L5 [81], anti-A16 [78], and anti-p4b/4b (R. Doms and B. Moss, unpublished).
Antibody to the A28 was prepared by immunizing rabbits with purified recombinant
protein provided by Gretchen Nelson, NIAID. K2 and A56 rabbit antisera were raised
against a synthetic peptide PFDITKTRNASFTNKYGTKT derived from K2 amino
acids 176-195 and SEKPDYIDNSNCSSVF derived from A56 amino acids 151-166
with the addition of a C-terminal cysteine for conjugation to keyhole limpet
hemocyanin (Covance Research Products, Denver, PA).  A monoclonal antibody
against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was obtained from
Covance.
2.2.6 Synthesis and purification of soluble A56/K2.
Ten roller bottles of RK13 cells were coinfected with 1 PFU per cell each of
vsA56TAPi"C3 and vK2i"A56"C3 for 2 h at 37
o
C.  After virus adsorption the cells
were washed twice with Dulbeccos’s phosphate buffered saline with calcium and
magnesium (Quality Biological Inc.). Then 50 ml of Opti-Mem (Invitrogen) with 2
mM IPTG was added and the infection was allowed to proceed for 48 h.  The medium
was clarified by centrifugation and any remaining debris removed by filtering through
a 0.45 !M membrane.  The medium was supplemented with glycerol to 10% final
concentration and NaCl to 400 mM. The protein was purified by binding to wheat
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germ agglutinin agarose (Vector laboratories, Burlingame, CA) and eluted with 500
mM N-acetyl-#-D-glucosamine (Calbiochem, La Jolla, CA).  The eluate was then
bound to streptavidin Sepharose, washed with phosphate buffered saline and eluted
with 1 mg/ml of biotin.
2.3 Results
2.3.1 Neutral pH Cell-Cell Fusion Requires the Entry/Fusion Complex.
The first goal of this study was to better understand neutral pH cell fusion that
occurs following infection with VACV deleted for the A56R or K2L gene.  Low pH
cell fusion of VACV requires a functional EFC, however this complex has not been
demonstrated to be required for neutral pH cell-cell fusion.  The function of the
proteins of the EFC in virus entry and fusion was initially characterized by
constructing conditional lethal viruses in which gene expression was regulated by
E.coli lac repressor [71, 78, 79, 81-85].  Repressing the synthesis of any of the entry
proteins produced viruses with a similar phenotype, mainly an inability of the virus
particle to penetrate the cell along with failure to trigger low pH cell fusion.  The
current strategy was to determine the effect of deleting the A56R or K2L gene from
one of the inducible mutants of the entry complex. If spontaneous fusion of infected
cells occurred when EFC gene was repressed, it would indicate an alternative
pathway of cell-cell fusion.
The vA28i was used as the parental inducible virus because regulation of A28
expression was stringently repressed in the absence of IPTG and assembly of the EFC
was prevented [85].  A56R and K2L genes were deleted individually from vA28i by
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replacing the viral gene with the coding sequence for EGFP to form vA28i"A56 and
vA28i"K2, respectively.  DNA sequencing confirmed the deletion of the A56R or
K2L gene. vA28i"A56 and vA28i"K2 stocks were prepared in the presence of IPTG
so that virions possessed A28 and were therefore able to infect cells. After infection
in the absence of IPTG, however, the progeny virions would lack A28 and be unable
to spread to neighboring cells.  Both recombinant viruses expressed EGFP regardless
of the presence or absence of IPTG but only formed plaques under the former
conditions. In the presence of IPTG, HeLa cells infected with vA28i"A56 or
vA28i"K2 formed large multinucleated syncytia visualized by fluorescence
microscopy (Figure 2-1).  No cell fusion was observed in the absence of IPTG for
either vA28i"A56 or vA28i"K2 even though the cells were infected as shown by
expression of EGFP (Figure 2-1).  The results showed the A28 protein, in addition to
its role in virus entry and low pH triggered cell-cell fusion, was required for cell-cell
fusion occurring at neutral pH in the absence of the A56R or K2L gene. It seems
likely that the other components of the EFC would also be required for neutral pH
cell fusion indicating the multicomponent EFC mediates both low pH and neutral pH
virus-induced membrane fusion.
2.3.2 The anti-fusion proteins A56 and K2 interact with the viral EFC.
A56 contains no putative enzymatic motifs and the serine protease inhibitor
active site of the K2 protein is not required to inhibit cell fusion.  This suggested the
proteins may regulate cell fusion through protein-protein interactions. To investigate
possible protein interaction of the A56 protein, a recombinant VACV called
40
Figure 2-1:  The EFC is required for neutral pH cell fusion.  HeLa cells were
infected with vA28i"A56 or vA28i"K2 in the absence (-) or presence (+) of IPTG.
After 24 h, the cells were examined under an inverted fluorescence microscope to
visualize cells expressing GFP encoded by the recombinant VACVs.  The percentage
of nuclei in syncytia, as defined by a cell containing 3 or more nuclei, is averaged
from two independent experiments.
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Figure 2-2: Tandem affinity purification of A56.
HeLa cells were infected with VACV WR or vA56TAP and the cells were disrupted
with Triton X-100.  The post-nuclear supernatants were purified successively on
streptavidin and calmodulin affinity columns. The bound proteins were eluted,
concentrated, resolved by SDS-PAGE and detected by staining with Coomassie blue.
The protein bands were excised from the gel, digested with trypsin and analyzed by
mass spectrometry. The identities of the proteins are indicated to the right of the
stained bands.  In one case, peptides corresponding to two proteins (G9 and I1) were
obtained from the same band. Marker proteins with masses in kDa are indicated at the
left.
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vA56TAP was constructed in which codons for streptavidin and calmodulin binding
peptides were fused in frame to the end of the A56R open reading frame. The TAP
tag did not compromise the function of the A56 protein, as syncytia did not form
when cells were infected with vA56TAP. Infected cells were lysed with Triton X-100
detergent and the post-nuclear supernatant was incubated with Sepharose beads
linked to streptavidin. The resin was washed extensively and the bound proteins were
eluted from the streptavidin beads by incubation with D-biotin.  The eluate was
subjected to a second affinity purification by incubating with Sepharose beads linked
to calmodulin.  The calmodulin Sepharose was washed and the bound proteins were
eluted with EGTA. The purified proteins were concentrated, resuspended with a
solution of LDS, resolved by polyacrylamide gel electrophoresis, and then visualized
by staining with Coomassie blue.  Cells infected with VACV lacking a TAP tag were
purified in parallel to serve as a negative control.  Multiple intensely stained bands
were observed in the A56TAP sample, but were absent from the control.  The protein
bands were excised and then digested with trypsin followed by mass spectrometry to
identify the peptides. The proteins corresponding to the observed peptides are
indicated next to the bands in figure 2-2. One of the bands corresponded to the K2
protein, confirming an association with A56. The intensity of the K2 band, however,
was much less than that of A56, even taking into account the difference in their
masses. This suggests either a surplus of A56 relative to K2, not all of the K2 was
bound to HA, or the complex partly dissociated during purification.   Interestingly
members of the EFC A16, G9 and J5 co-purified with A56.  Several other proteins,
namely calmodulin and the VACV products C3, I1 and O2 also copurified with A56
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and were identified by mass spectrometry (Figure 2-2). Calmodulin undoubtedly
came from the affinity beads. C3 is a secreted modulator of complement activation
[58, 59] I1 is a DNA telomere binding protein [189], [190] and O2 is a non-essential
glutaredoxin [191 {Rajagopal, 1995 #554, 192]. Although these additional bands
were not detected in the control lane (Figure 2-2), any biological significance of the
latter interactions with A56 remains to be determined.
Western blotting with specific antisera to A21, A28 and L5 was used to
identify three additional EFC proteins recovered after TAP of A56 (Figure 2-3). It is
likely that the other entry proteins G3 and H2 were also present, though antibodies to
these proteins were not available to confirm this.  Cells infected with wild type
VACV lacking a tag on A56 did not associate with A21, A28 and L5 when subjected
to TAP, even though these proteins were present in the starting material (Figure 2-3).
Furthermore, antisera to K2 and A16 were used as positive controls and antisera to
D8, an MV membrane protein not associated with the EFC, and the cellular protein
GAPDH as negative controls.  In this experiment a small amount of GAPDH was
detected; however this was non-specific as it was not dependent on K2 (see next
section). Collectively the mass spectrometry and Western blotting data indicated that
at least 6 of the 8 EFC proteins were associated with A56 either directly or indirectly.
2.3.3 A56 does not bind the EFC in the absence of K2.
Regulation of infected cell fusion requires K2 as well as A56, yet the role of
the individual proteins in the interaction with the EFC was unknown.  Therefore the
primary binding of the EFC may be mediated by either A56 or K2.  To investigate if
A56 alone was able to associate with the entry complex, the K2L gene of vA56TAP
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was replaced with DNA encoding EGFP.  As expected, cells infected with the K2L
deleted virus vA56TAP"K2 fused to neighboring cells. When extracts of cells
infected with vA56TAP"K2 were subjected to TAP in parallel with extracts of cells
infected with vA56TAP, EFC proteins were only detected in the latter (Figure 2-3).
Cells infected with vA56TAP"K2 expressed A16, A21, A28 and L5 similar to those
infected with either WR or A56TAP (Figure 2-3).  The results suggested K2 is
important for interaction with the EFC, possibly by direct association.
2.3.4 Both K2 and A56 are needed for association with the EFC.
The inability of A56 to associate with the EFC in the absence of K2 suggested
the EFC interacts with A56/K2 through K2 and only indirectly with A56.  To test this
hypothesis, a recombinant VACV was constructed in which K2 has a TAP tag and
A56 was deleted. The virus created in several steps, the first was to make vK2TAP, a
recombinant VACV encoding K2 with a TAP tag appended to the C-terminus. A
small increase in syncytia formation was noted in cells infected with vK2TAP
suggesting the presence of the TAP tag slightly affected the function of K2, though
the amount of cell fusion was well below the level of a K2 deletion virus. Western
blot analysis of affinity purified K2 showed the protein co-purified with both A56 and
components of the EFC and confirmed that the tag did not greatly compromise the
function of K2 (shown later).  To determine whether K2 was sufficient for interaction
with the EFC the A56 gene was removed to construct vK2TAP"A56. Cells infected
with vK2TAP"A56 formed large multinucleated syncytia consistent with the
phenotype observed upon infection with an A56 deletion mutant.  Initial experiments
suggested the EFC did not associate with affinity purify
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Figure 2-3: Western blot analysis of A56TAP.
Mock infected cells (M) or cells separately infected with VACV WR, vA56TAP or
vA56TAP"K2 were subjected to tandem affinity purification over successive
streptavidin and calmodulin affinity resins.  The bound proteins were eluted, resolved
by SDS-PAGE, and detected by Western blotting with antibodies to the indicated
proteins.  Components of the EFC are represented by: A16, A28, A21, and L5; D8 is
an MV protein and absent from the EFC; GAPDH is a cellular protein used as a
control. Starting material is designated PreTAP, samples subjected to dual affinity
purification are labeled TAP.  Viruses are noted at the top.
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Figure 2-4: Entry proteins co-purify with K2TAP only in the presence of A56.
Cells were mock infected or infected separately with VACV WR, vK2TAP or
vK2TAP"A56.  The post-nuclear supernatent was affinity purified sequentially over
streptavidin and calmodulin Sepharose.   The bound material was eluted, separated by
SDS-PAGE and analyzed by Western blotting with antibodies to the proteins A56,
K2, A16, A21, L5 and p4b as indicated.  Starting material is labeled PreTAP.
Affinity purified samples referred to as TAP.  The - and + signs indicate the absence
or presence of brefeldin A, respectively.
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K2TAP in the absence of A56.  However, in the absence of A56 the K2 protein was
partially secreted into the medium, since K2 relies on association with A56 for
membrane association. To prevent secretion and potentially allow more opportunity
for K2 to interact with the EFC, the antibiotic brefeldin A was used to disrupt the
Golgi apparatus and prevent protein trafficking along the secretory pathway [193,
194].  Brefeldin A has been shown to have little effect on the formation of MV, while
significantly reducing the amount of EV [195]
To determine whether A56 was required for K2 to bind the EFC, HeLa cells
were infected with VACV WR, vK2TAP or vK2TAP"A56 in the presence or
absence of 10 µg/ml of brefeldin A.  Cell lysates from the starting material confirmed
A56 was not synthesized in cells infected with vK2TAP"A56 (Figure 2-4). Brefeldin
A altered the mobility of glycosylated A56 expressed in cells infected with VACV
WR or vK2TAP which was expected due to a failure of the protein to transit through
the Golgi apparatus (Figure 2-4). There appeared to be more A56 in the presence of
brefeldin A, possibly because shedding of EVs was prevented. Similarly, brefeldin A
increased the amount of K2 and changed the mobility of the protein, particularly in
the absence of A56.  There was no noticeable effect of brefeldin A on the non-
glycosylated EFC proteins or on the core protein p4b (Figure 2-4).  K2 purified from
cells infected with vK2TAP demonstrating an association with A56 and the EFC
proteins A16, A21, A28 and L5 in the absence or presence of brefeldin A (Figure 2-
4).  K2 did not interact with p4b indicating the interaction was specific. In the
absence of A56, the K2 protein was unable to associate with A16, A21, A28 and L5
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even though brefeldin A increased the amount of K2.  These results show both A56
and K2 are needed to association with the EFC.
2.3.5 Association of A56 and K2 with a TAP-tagged EFC.
The EFC has been shown to copurify with both a TAP tagged A56 and a TAP
tagged K2 protein. To confirm this interaction, the reciprocal experiment was
performed by constructing an additional recombinant VACV with DNA encoding the
TAP tag at the 3’ terminus of the A28L gene.  The A28 protein was chosen as a
representative member of the EFC and the protein was previously shown to exhibit
normal function with the addition of the influenza HA epitope, suggesting the protein
may tolerate the addition of the TAP tag [85]. The recombinant VACV vA28TAP
grew to high titers indicating no defect in A28 function.  The vA28TAP was used to
construct another recombinant VACV in which the K2L gene of vA28TAP was
replaced with the gene encoding EGFP.  Cells infected with vA28TAP"K2 formed
syncytia at neutral pH.  Lysates from HeLa cells infected with VACV WR, vA28TAP
or vA28TAP"K2 were subjected to tandem affinity purification and then analyzed by
Western blotting.  As expected, the mobility of the A28 protein was reduced in cells
infected with A28TAP due to the increase in mass caused by the TAP tag, while K2
was absent in cells infected with vA28TAP"K2 (Figure 2-5).  Both A56 and K2 co-
purified with the A28TAP entry protein (Figure 2-5). The interaction between A28
and A56/K2 was specific as neither the core protein p4b nor the cellular protein
GAPDH co-purified with A28TAP, in addition no proteins were detected from the
affinity-purified lysates of VACV WR (Figure 2-5). The major A56 band did not
associate with A28TAP when the protein was purified from the lysate of
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Figure 2-5: A TAP-tagged A28 protein associates with A56 and K2.
Cells were infected individually with VACV WR, vA28TAP or vA28TAP!K2 as
indicated and lysed.  The A28 protein was purified sequentially by streptavidin and
calmodulin chromatography.  The co-purifying proteins were eluted, resolved by
SDS-PAGE, and detected by Western blotting with antibodies to the proteins: A56,
K2, A28, p4b, GAPDH as indicated. PreTAP, starting material; TAP, affinity purified
samples.
50
vA28TAP"K2 (Figure 2-5). A much less intense doublet migrating faster than the
major A56 bands was observed to copurified with A28TAP in the presence and
absence of K2 (Figure 2-5).  Initially our thought was that the doublet represented
cross-reactivity of the anti-A56 peptide antibody, however the same result was
obtained when the Western blot was carried out with a monoclonal antibody against
A56.  This suggests a minor form of A56 is able to bind A28TAP even in the absence
of K2.  In the absence of K2, the major bands of A56 fail to associate with A28TAP
confirming the importance of K2 for binding the EFC.
2.3.6 Interaction of soluble A56/K2 with the EFC.
To further characterize the association between the fusion regulatory proteins
and the EFC, a soluble form of A56/K2 was prepared.  The basic idea was to prepare
two recombinant VACVs that each inducibly over expressed either K2 or a secreted
form of A56 using vT7lacOI [66] as the starting virus. One of the recombinant
VACVs had a deleted A56 gene and a K2 gene regulated by the bacteriophage T7
promoter and E. coli lac operator. A second recombinant VACV possessed an
inducible A56 with the membrane anchor and cytoplasmic tail sequences substituted
for codons of the TAP tag. Pilot experiments confirmed secretion of a K2/A56TAP
complex from co-infected cells, yet the C3 protein also associated with the complex.
(Note that association of C3 with the full-length K2/A56 complex is shown in Figure
2-2). The C3 protein is a non-essential virus-encoded host defense protein and was
removed by replacing the gene with one encoding EGFP in both recombinant VACVs
to form vK2i"A56"C3 and vsA56TAPi"C3 which inducibly expressed K2 and a
soluble TAP-tagged A56 in the absence of C3.
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To isolate a soluble complex of A56 and K2 RK13 cells were coinfected with
vK2i"A56"C3 and vsA56TAPi"C3 in low serum medium supplemented with IPTG.
The presence of IPTG was required to induce protein expression, while the low serum
reduced the level of contaminating proteins.  Both A56 and K2 are glycosylated so an
immobilized lectin, wheat germ agglutinin, was used to concentrate the proteins from
the medium.  Following this step the complex was isolated by an affinity step with
streptavidin Sepharose.  This two-step purification isolated a soluble complex of A56
and K2 that was free of major contaminating proteins (Figure 2-6A).
To investigate an interaction between purified soluble A56TAP/K2 and the
EFC, the infected cell lysate needed to lack endogenous A56 and K2.  To facilitate
this, a recombinant VACV, v"A56"K2 was constructed by sequential replacement of
the A56R and K2L genes with DNA encoding EGFP and HcRED, respectively.
Deletion of A56 and K2 was confirmed by Western blot analysis (Figure 2-6). The
soluble complex of A56TAP/K2 was incubated with a post-nuclear lysate isolated
from HeLa cells infected with v"A56"K2 or mock infected. Affinity purification of
the soluble A56TAP/K2 was determined by TAP, utilizing the tag on the recombinant
A56TAP protein. Western blot confirmed an association between soluble
A56TAP/K2 and A16, A21, A28 and L5, but not with the core protein p4b (Figure 2-
6B).  The  EFC only co-purified with the soluble A56TAP/K2, as none of the entry
proteins were detected in its absence.  The secreted form of A56TAP appears to be a
homogenous, fully glycosylated protein, whereas A56TAP from infected cell lysates
(shown on the right of Figure 2-6B) is heterogeneous reflecting varying stages of
glycosylation.
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Figure 2-6: Soluble A56/K2 interacts with the EFC.
(A) Soluble A56/K2 was isolated by affinity purification from the medium of cells
co-infected with vK2i"A56"C3 and vsA56TAPi"C3 in the presence of IPTG.  A
complex of A56/K2 was purified by a 2-step procedure using immobilized wheat
germ agglutinin and streptavidin. Following concentration, the purified proteins were
analyzed by SDS-PAGE and silver staining. (B) A post nuclear lysate of mock
infected HeLa cells or cells infected with v"A56"K2 was incubated with the purified
soluble A56/K2.  The A56/K2 complex was tandem affinity purified, separated by
SDS-PAGE and analyzed by Western blotting by using antibodies to the proteins
indicated on the left.
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2.4 Discussion
Entry of VACV core is preceded by fusion of the MV membrane with the
plasma membrane at neutral pH [91] or with the endosomal membrane at low pH
[94]. Fusion of MV at the plasma membrane is greatly enhanced by lowering the pH
of the medium below 6, a process that is thought to mimic the decrease in pH within
the endosome [94].  At late times during an infection, briefly lowering the pH of the
medium triggers cell-cell fusion, a process that depends on cell surface EV (called
fusion from within) [152, 165, 166].  Cell fusion also occurs when cells are
inoculated with large numbers of purified MV and subsequently treated with low pH
(called fusion from without) [166].  Cells infected with VACV normally do not fuse,
but deletion of the A56 or K2 protein leads to spontaneous cell fusion of infected
cells at neutral pH [167-170].
EV is required for infected cell fusion trigger by low pH as well as cell fusion
associated with deletion of A56 (and presumably K2), indicating virus-cell fusion and
cell-cell fusion are closely related phenomena.  Previous investigations have revealed
virus-cell fusion and low pH-induced cell fusion depended on a conserved
multiprotein EFC [84, 94]. The study described in this chapter demonstrated neutral
pH cell fusion requires the A28 protein.  Repressing synthesis of A28 prevents
formation of the EFC [84].  It is likely that other proteins of the complex will also be
required for neutral pH cell fusion.  The first stage in the development of cell fusion
is thought to be fusion between MV and cell membrane (Figure 1-4).  The absence of
a functional EFC would prevent virus-cell fusion and as a result the latter steps would
not occur.
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The mechanism by which A56 and K2 regulate cell fusion is unknown.  The
A56 protein has no putative catalytic motifs and mutations in K2 that disrupt the
SERPIN  activity have no effect on syncytia formation.  Given this information it was
suspected that A56/K2 might inhibit cell fusion through protein-protein interaction.
To investigate this hypothesis a number of recombinant VACV were constructed with
the TAP tag attached to A56, K2 or the A28 EFC protein.  Both A56 and K2 were
observed by a combination of mass spectrometry and Western blotting to interact
with proteins of the EFC.  A56 was unable to interact with the EFC in the absence of
K2, and efficient interaction of K2 with the EFC required A56.  A minor form of A56
was observed to copurified with TAP-tagged EFC in the absence of K2, although the
significance is not yet understood. The requirement of both A56 and K2 to efficiently
bind the EFC correlates with the need of both proteins to efficiently prevent
spontaneous fusion of infected cells. The dynamics of the interaction between the
EFC and A56 and K2 remain to be studied.  It is unknown whether a conformational
change occurs within A56 or K2 upon associating with one another.  Alternatively,
the conformation of the complex of A56 and K2 may be required to bind the EFC.
Both A56 and K2 are present in the EV membrane [184] and are located
within the plasma membrane as well [172].  It is suspected that plasma membrane
localization of A56/K2 is important for preventing re-infection of cells by progeny
extracellular virions.  In order for A56/K2 to interact with the EFC within the MV
membrane, the outer EV membrane must first be disrupted.  It was recently reported
that the EV membrane is ruptured by interaction with cell surface GAGs [97].
55
The interaction of A56/K2 with the EFC was observed to occur post-lysis.
This was shown by the ability of soluble A56/K2 to interact with the EFC from an
infected cell lysate devoid of endogenous A56/K2.  Therefore under the experimental
conditions the addition of the detergent lysis the cells and allows A56/K2 to interact
with the EFC.  Additional investigation will be required to determine the proteins of
the EFC that mediate an interaction with A56/K2.
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Chapter 3: The VACV fusion regulatory proteins A56 and K2
interact with a subcomplex of A16 and G9
3.1 Introduction
VACV induces cell fusion following low pH treatment of infected cells or
spontaneously at neutral pH when either the A56R or K2L gene is absent.  VACV
entry and fusion requires a conserved multiprotein complex of at least eight proteins
that resides within the MV membrane.  The EFC is essential for entry of both the MV
and EV forms of the virus as is also required for low pH cell-cell fusion, while in the
previous chapter the A28 entry protein was shown to be essential for neutral pH cell
fusion associated with deletion of A56 or K2.  Therefore virus-cell fusion, neutral cell
fusion and low pH cell fusion all depends on the viral EFC.  Assembly of the EFC
does not occur in the absences of a single entry protein, although the remaining entry
proteins are stable and localize to the MV membrane.
Little is known about the mechanism by which A56 and K2 regulate cell
fusion.  Tandem affinity purification of the A56 protein was utilized to identify a
novel protein interaction with the EFC, suggesting the anti-fusion activity of A56 and
K2 may be mediated through an interaction with the viral entry proteins.  Both fusion
regulatory proteins were required to bind the EFC; neither A56 nor K2 alone was
sufficient.  The previous chapter did not determine the protein within the EFC
required for an interaction with A56/K2.  To determine the minimal components of
the EFC required for binding to A56/K2 a series of conditional lethal viruses were
constructed in which various entry proteins were repressed and interaction with
A56/K2 were assessed.  Our analysis revealed both A16 and G9 were needed to bind
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A56/K2 as neither  A16 nor G9 alone bound efficiently to A56/K2.  Furthermore A16
and G9 were shown to interact with one another in transfected cells suggesting the
two proteins directly interact within the EFC.
3.2 Material and Methods
3.2.1 Cells and virus.
BS-C-1 (ATCC CCL-26), HeLa S3 (ATCC CCL-2.2) suspension cells were
grown as described in chapter 2, section 2.2.1. 293TT cells, stably expressing the
large T antigen, were provided by Chris Buck [196], and were grown in Dulbecco’s
minimum essential medium (Quality Biological) supplemented with 10% fetal bovine
serum, 2 mM L-glutamine and 400 !g/ml hygromycin (Invitrogen, Carlsbad, CA).
The Western Reserve (WR) strain of VACV was used in the construction of all
recombinant viruses unless noted otherwise. General procedures for preparing and
titrating stocks were done as previously described in chapter 2, section 2.2.1.
3.2.2 Plasmid and recombinant VACV construction.
The recombinant viruses constructed for this study (Table 3-1) were:
vA28iA56TAP, vA21iA56T A P , vA28iA56T A PJ5 Flag, vA28iA56T A PG93XFlag,
vA28iA163XFlag, vA28iG93XFlag, vA16iA56TAPG93XFlag, and vG9iA56TAP (where i
indicates an inducible gene, TAP refers to a tandem affinity tag, 3XFlag indicates 3
copies of the Flag epitope). Recombinant viruses were screened by PCR to confirm
the absence of parental virus and the sequence of the inserted DNA was confirmed.
The vA28iA56TAP, vA21iA56TAP, vA16iA56TAP and vG9iHAA56TAP were constructed
from vA28i [85], vA21i [79], vA16i [78] and vG9iHA [83], respectively by appending
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Table 3-1. Recombinant VACV
Recombinant virus     Parent (Reference) Description
vA16i vT7lacOI      [66] Inducible A16
vA16iA56TAP vA16i           [78] Inducible A16; A56-TAP
a




vA21i vT7lacOI      [66] Inducible A21
vA21iA56TAP vA21i           [79] Inducible A21; A56-TAP
a
vA28i vT7lacOI      [66] Inducible A28-HA
c









































1 copy of Flag tag at N-terminus
e 
1 copy of N-terminal HA tag
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the codons for a C-terminal TAP tag to the A56 gene. The DNA used to construct the
C-terminal TAP tag has been described in chapter 2, section 2.2.3.  vA28iA56TAP was
the parental virus for the construction of vA28iA56TAPJ5Flag.   Overlapping PCR
(Accuprime Pfx; Invitrogen) was used to assemble the DNA used for recombination.
The layout of the DNA sequence for the J5Flag construct from the 5’ to 3’ was as
follows: (i) 500 bps of DNA sequence upstream of the J5R gene, (ii) EGFP expressed
from the I1L promoter, (iii) 70 nucleotides containing the J5R promoter and (iv) the
initial methionine of J5R, followed by the DNA sequence for the Flag epitope
(DYKDDDK) and then the remaining DNA sequence of the J5R gene.  The
recombinant PCR product was cloned into pCR-BluntII-TOPO (Invitrogen) and
verified by DNA sequencing.  The J5Flag plasmid was linearized by cleavage with a
unique restriction endonuclease.  BS-C-1 cells were infected with vA28iA56TAP for 1
h, then transfected with the linearized plasmid using Lipofectamine 2000
(Invitrogen). IPTG was added to the medium at 100 µM to allow expression of the
inducible A28 gene.  The parental and recombinant viruses were distinguished by the
GFP fluorescence of the latter.  Recombinant plaques were clonally isolated through
3 rounds of plaque purification.
vA28iA56TAPG93XFlag and vA28iG93XFlag were constructed from vA28iA56TAP
and vA28i, respectively.  vA16iA56TAPG93XFlag was constructed sequentially by first
generating vA16iA56TAP from vA16i. The 3XFlag was added to the G9 protein to
form vA16iA56TAPG93XFlag, vA28iA56TAPG93XFlag, vA28iG93XFlag as follows.  The
G9R gene was PCR amplified from genomic DNA of the Western Reserve (WR)
strain (ATCC VR-1354, accession number AY243312).  The 3XFlag epitope was
60
appended to the C terminus of G9 prior to the stop codon.  This was followed by the
coding sequence of the Discosoma sp. red fluorescent protein (DsRed) expressed
from the I1L intermediate promoter for screening of recombinant viruses. The L1R
gene was PCR amplified along with 90 bps upstream of the gene to include the L1R
promoter. Recombinant PCR was utilized to add L1R with the promoter after the
DsRed coding sequence. The promoter for the LIR gene is located within the C-
terminal codons of G9. To conserve expression of the L1R gene, the C-terminus of
G9 was duplicated causing a direct repeat of DNA sequence before and after the
DsRed gene.  Direct repeats are unstable in the virus genome [197].  Therefore to
prevent the eventual loss of the DsRed gene the codons of the final 33 amino acids
from G9 were altered, while conserving the amino acid sequence. The recombinant
G93XFlag PCR was cloned into pCR-BluntII-TOPO and verified by DNA sequencing.
Recombinant viruses were generated by infecting BS-C-1 cells with the appropriate
parental virus and then transfecting  linearized G93XFlag plasmid. Recombinant viruses
were distinguished from parental by DsRed fluorescence and were clonally isolated
through 3 rounds of plaque purification.
3.2.3 A16 and G9 Codon Optimization.
The DNA sequence for the VACV WR A16L and G9R genes was optimized
(Geneart, Regensburg, Germany) to alter codon usage and G-C content to improve
RNA processing and translation. The optimized A16L and G9R genes were PCR
amplified with oligonucleotides that contained the sequence of the influenza virus HA
or 3XFlag epitope appended to the C-terminus of the respective ORFs. The PCR
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products of A16HA and G93XFlag were cloned into the directional TOPO vector
pcDNA3.1 (Invitrogen) and sequenced to confirm proper insertion and sequence.
3.2.3 Affinity purification.
BS-C-1 cells (6 x10
6
) were infected at a multiplicity of 3 to 5 plaque forming
units per cell in EMEM with 2% FBS.  After 24 h the cells were scraped into the
medium and subjected to low speed centrifugation.  The cell pellet was washed once
by resuspending in 150 mM NaCl with 50 mM Tris-HCl (pH 7.5).  The cells were
then lysed with ice-cold SBB [1% Triton X-100 (Sigma, St. Louis, MO), 150 mM
NaCl, 50 mM Tris-HCl (pH 7.5)] supplemented with complete protease inhibitor
(Roche, Indianapolis, IN) and rotated at 4 
o
C for 30 min.  The lysate was pelleted at
4
o
C in a benchtop centrifuge at 20,000 x g for 10 min and the postnuclear supernatent
was collected and 50 µl saved for analysis. Tandem affinity purification was carried
out as previously described in chapter 2, section 2.2. Single step purifications were as
follows. Packed beads (20-30 µ l) of either streptavidin Sepharose (Millipore,
Billerica, MA) or anti-Flag conjugated agarose (Sigma) were washed once with 1 ml
of lysis buffer and the postnuclear supernatant was added to the affinity resin and
rotated overnight at 4 
o
C. The affinity resin was washed 5 times with 1 ml of SBB
prior to elution.  The bound material was eluted from the anti-Flag agarose by added
50 !l of 1X LDS sample buffer (Invitrogen) supplemented with reducing agent
(Invitrogen) and incubated at 100 
o
C for 5 min.  The beads were pelleted by
centrifugation and the supernatent was collected.  Bound material was eluted from the
streptavidin Sepharose by incubation with 300 µl of lysis buffer supplement with 2
mM d-Biotin (US Biological, Swampscott, MA).  The elution was repeated two times
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and the eluates were combined prior to concentration by precipitation with
trichloroacetic acid. The precipitated material was resuspended in 40 µl of 1x LDS
buffer with reducing agent.
3.2.5 Transfection and coimmunoprecipitation.
293TT cells were plated at a density of 2x106 per 9.2 cm2 the day before
transfection in 10% DMEM plus glutamine, but without hygromycin.  Cells were
transfected with 2 µg of total DNA using Lipofectamine 2000 (Invitrogen).  After 24
h fresh 10% DMEM was added and the incubation continued for an additional 24 h at
which time cell extracts were prepared and subjected to immunoprecipitation.
3.2.6 Western blotting and antibodies.
Samples were loaded onto a 4-12% Novex NuPAGE acrylamide gel
(Invitrogen) and separated by electrophoresis using 2(N-morpholino)ethanesulfonic
acid buffer (Invitrogen). The protein samples were transferred to a nitrocellulose
membrane and then blocked with 5% nonfat milk in TBST. Primary antibody was
incubated a minimum of 1 h prior to extensive washing with TBST. The secondary
antibodies (Pierce, Rockford, IL) were diluted in 5% nonfat milk TBST and incubated
for at least 1hr. The nitrocellulose membrane was washed and then developed with
Dura or Femto Chemilumenscent substrate (Pierce). The antibodies were stripped
from the nitrocellulose by incubating 20 min at 55 
o
C with Restore (Pierce).
Antibodies to A56 (chapter 2, section 2.5), K2 (chapter 2, section 2.5), A21 [79], L5
[81], A16 [78], and p4a/p4b (R. Doms and B. Moss, unpublished data) were used in
Western blot analysis. A monoclonal antibody (conjugated to horseradish peroxidase)
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against the influenza hemagglutinin epitope was acquired from Bethyl laboratories
(Montgomery, TX).  The anti-Flag M2 monoclonal antibody was obtained from
Sigma (St. Louis, MO) and a monoclonal antibody to the cellular glyceraldehyde-3-
phosphate dehydrogenase was purchased from Covance Research (Princeton, NJ).
The rabbit antiserum to H2 and A28 was generated by immunizing rabbits with
purified recombinant H2 or A28 proteins, respectively and provided by Gretchen
Nelson, NIAID.  Peptide antibody was generated to the G3 protein by immunizing
rabbits with the synthetic peptide [SLNGKKHTFNLYDDNDIRT] coupled to
keyhole limpet hemocyanin through an N terminal cysteine (Covance).
3.3 Results
3.3.1 A56/K2 interacts with a subset of the proteins within the EFC.
The interaction of A56/K2 with the EFC was described in chapter 2.  Both
A56 and K2 polypeptides were required to interact with the EFC, although the entry
proteins required for the interaction were not determined.  Our analysis was based on
previous observations that (i) the viral membrane is required for assembly of the EFC
and (ii) that the EFC fails to form in the absence of A28 or A21 even though the
remaining EFC proteins are incorporated into the viral membrane [84].  It may be
possible by repressing synthesis of A28 and A21 to identify either individual
polypeptides or previously uncharacterized subcomplexes of the EFC capable of
interacting with A56/K2. To implement this strategy two recombinant viruses were
constructed, vA28iA56TAP and vA21iA56T A P , in which A28 and A21 were
conditionally expressed, respectively. Conditional expression of A28 and A21 was
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regulated by components of the E. coli lac operon in combination with the T7 phage
DNA-dependant RNA polymerase, such that viral gene expression depended on the
addition of IPTG.  Both recombinant viruses were constructed with a TAP tag
appended to the C-terminus of the A56R gene to allow purification of the A56/K2
heteromultimer along with any associating polypeptides. In addition, A28 had a C-
terminal HA epitope tag.
HeLa cells were infected with VACV strain WR, vA56TAP (chapter 2, section
2.3), vA28iA56TAP (+ and – IPTG), vA21iA56TAP (+ and – IPTG), or mock infected.
VACV WR, with an untagged A56 was used as a negative control for nonspecific
interaction during affinity purification, while vA56TAP with a constitutively expressed
A28 was used as a positive control.  The stocks of vA28iA56TAP and vA21iA56TAP
were prepared in the presence of IPTG so that the virus particles contained A28 and
were infectious, but synthesis of A28 or A21 during the next cycle depended on the
addition of IPTG.  At 24 h post infection, the cells were lysed with Triton X-100
detergent and the post-nuclear supernatant was subjected to TAP on streptavidin and
calmodulin Sepharose columns.  The proteins in the final eluate were concentrated,
separated by SDS-PAGE, and detected by Western blotting with specific antibodies.
Western blotting of the starting material of cells infected with vA28iA56TAP
and vA21iA56TAP, confirmed synthesis of A28 and A21, respectively, depended on
IPTG (Figure 3-1, PreTAP). The slightly slower electrophoretic migration of A28 in
the lysate of vA28iA56TAP was due an HA epitope tag on the C terminus of the
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Figure 3-1:  A56/K2 physically associate with A16.
 HeLa cells were mock infected (M) or infected with VACV WR, vA56TAP,
vA28iA56TAP (+ and – IPTG) and vA21iA56TAP (+ and – IPTG). After 24 h the cells
were lysed with Triton X-100 and the A56 protein was affinity purified sequentially
over streptavidin and calmodulin Sepharose. The starting material (PreTAP) and
purified samples (TAP) were separated by SDS-PAGE and analyzed by Western
blotting using antibodies to the entry proteins: A16, A28, A21 and L5 as well as
antibodies to the A56 and K2 proteins. Secondary antibodies conjugated to
horseradish peroxidase were used for detection by chemiluminescence. The
recombinant viruses are listed at the top and proteins targeted by the antibodies are
listed in the center.
66
protein.  Repression of either A28 or A21 had no effect on the synthesis or stability of
the other proteins examined. A56 and K2 were resolved as multiple bands due to
alternative initiation codons for A56 as well as glycosylation.
Following affinity purification of A56 from vA56TAP, vA28iA56TAP (+IPTG)
and vA21iA56TAP (+ IPTG) the A56 protein was observed to interacted with K2 as
well as the EFC, as represented by A16, A28, A21 and L5 (Figure 3-1, TAP).
However, when A28 was repressed by omitting IPTG, K2 and A16 still co-purified
with A56 but only trace amounts of A21 and L5 were detected (Figure 3-1, TAP).
Similarly, when A21 was repressed, K2 and A16 were detected after affinity
purification of A56 but only trace amounts of A28 and L5. These results likely
indicate the fully assembled EFC is not required for interaction with A56/K2 and
suggest A16 alone or a subcomplex of polypeptides that includes A16 binds to
A56/K2.  However, the association of A56/K2 with the four other entry proteins (G3,
G9, H2 and J5) was not examined because appropriate antibodies for detection were
not available at the time of the experiment.
3.3.2 A16 and G9 selectively copurify with A56/K2.
To determine if G3, G9, H2, and J5 were important for the interaction
between the EFC and A56/K2 several additional recombinant viruses were
constructed with epitope tags on G9 or J5.  In addition, antibodies were acquired to
G3 and H2. The recombinant virus vA28iA56TAPJ5Flag encoded an inducible A28,
TAP-tagged A56, and J5 with the Flag epitope fused to the N terminus. Cells were
infected separately with VACV WR, vA56TAP or vA28iA56TAPJ5Flag (+ and – IPTG).
After 24 h, the cells were lysed and the starting material was analyzed along with the
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affinity-purified samples.  Western blots of the starting material confirmed A28 was
stringently repressed in the absence of IPTG, furthermore both J5 and G3 were
detected using Flag tag and G3 peptide antibody, respectively (Figure 3-2A, PreTAP).
The true J5 band could be distinguished from the upper and lower background bands
by its absence from cells infected with VACV WR and vA56TAP.  The core protein
A3 (p4b) was used as a negative specificity control for the affinity purification. Bands
corresponding to A56, K2, A16, A28, A21, L5 and G3 were detected after affinity
purification of A56 from cells infected with vA56TAP (Figure3-2A, TAP). The same
proteins, as well as J5 Flag, were detected after affinity purification of cells infected
with vA28iA56TAPJ5Flag in the presence of IPTG (Figure 3-2A, TAP). However, in
the absence of IPTG, cells infected with vA28iA56TAPJ5Flag did not express the A28
protein and only K2 and A16 co-purified with A56.  Therefore, neither J5 nor G3
interacted with A56/K2 when the A28 protein is repressed and the EFC does not
assemble.
The second virus constructed was vA28iA56TAPG93XFlag. As its name implies,
expression of A28 was inducible, A56 was TAP-tagged, and G9 had three copies of
the Flag tag (at the C-terminus). Cells were infected with VACV WR or
vA28iA56TAPG93XFlag (+ and – IPTG). At 24 h after infection, the cells were lysed
and analyzed directly or after streptavidin affinity purification, as the calmodulin step
was not found to be required. Western blots of the starting material from cells
infected with vA28iA56TAPG93XFlag  (- IPTG) showed A28 was repressed while both
the  epitope tagged  G93XFlag and H2 were expressed (Figure 3-2B, PreTAP). The use
of 3 copies of the Flag epitope enhanced the detection of G9 over background bands.
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Figure 3-2:  A16 and G9 selectively co-purify with A56/K2.
(A) HeLa cells were mock infected (M) or infected individually with VACV WR,
vA56TAP, vA28iA56TAPJ5Flag with (+) or without (–) IPTG.  After 24 h, the A56
protein was isolated from the infected cell lysates by binding successively to
streptavidin and calmodulin beads.  Western blotting was performed on the starting
material (PreTAP) and affinity purified proteins (TAP).  (B) BS-C-1 cells were mock
infected (M) or infected with VACV WR or vA28iA56TAPG93XFlag (+ or – IPTG).
After 24 h, the A56 protein was isolated by binding to streptavidin Sepharose.
Western blotting was performed on the starting material (Start) and affinity purified
proteins (Streptavidin) as above.
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Figure 3-3: A56/K2 binds to affinity purified A16 and G9.
 BS-C-1 cells were mock infected (M) or infected with VACV WR, vA28iA163XFlag
(+ or – IPTG), vA28iG93XFlag (+ or – IPTG). Infected cells were harvested after 24h
and lysed with Triton X-100. The lysate was cleared by centrifugation and the A16
and G9 polypeptides were isolated by binding to agarose beads conjugated with Flag
antibody. The eluate (Flag IP) and starting material (Start) were separated by SDS-
PAGE and analyzed by Western blotting with antibodies to the viral proteins A56,
K2, A28, A16 and A21 as indicated in the center. The viruses are indicated at the top
of the figure.
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A56, K2, A16, G9, A28 and H2 were detected after affinity purification of proteins
from cells infected with vA28iA56TAPG93XFlag ( + IPTG), but only K2, A16 and G9
co-purified with A56 in the absence of IPTG (Figure 3-2B, TAP). The A3 core
protein (p4b) was not detected in the presence or absence of IPTG. Collectively, the
affinity purification experiments indicated that of the eight EFC proteins, A16 and G9
interacted most directly with A56/K2.
3.3.3 A56/K2 copurify with A16/G9.
The reciprocal experiment was carried out to confirm the interaction of A16
and G9 with A56/K2. To implement this, two additional epitope tagged viruses were
constructed.  Both recombinant VACVs inducibly expressed A28, while G9 and A16
had a 3XFlag epitope attached to the C terminus in vA28iG93XFlag and
vA28iA163XFlag, respectively. Cells were infected with VACV WR, vA28iG93XFlag
(+ and – IPTG) or vA28iA163XFlag (+ and – IPTG). After 24 h, the cells were collected
and the postnuclear supernatant was incubated overnight with anti-Flag antibody
covalently linked to agarose beads, which were then washed extensively prior to
elution of the bound material.  The eluted proteins were resolved by SDS-PAGE and
detected by Western blotting. Analysis of the starting material indicated that A28 was
stringently regulated and that each of the constructs expressed A56, K2, A16 and A21
(Figure 3-3, Start). The slower migration of A16 from samples infected with
vA28iA163XFlag compared to wild type was due to the 3XFlag epitope. A21 was
analyzed as a representative EFC protein to confirm that the complex was not
assembled in the absence of A28. As anticipated, A16 or G9 interacted with A21 only
when A28 was synthesized (+ IPTG) (Figure 3-3, Flag IP). Nevertheless, A16 and G9
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interacted with A56 and K2 even when A28 was repressed (Figure 3-3, Flag IP).
Thus, the interaction of A56/K2 with A16 and G9 occurred regardless of the affinity
tag and whether it resided on A56, A16 or G9.
3.3.3 Both A16 and G9 are required for  their association with A56/K2.
In the above experiments, A16 and G9 always co-purified with A56/K2 and
vice versa. Additional recombinant viruses were constructed to determine whether
expression of both A16 and G9 were required for a stable interaction with A56/K2.
The recombinant vA16iA56TAPG93XFlag expressed an inducible form of A16, TAP-
tagged A56 and G9 with a 3X Flag tag. Cells were infected with either VACV WR or
vA16iA56TAPG93XFlag (+ and – IPTG) for 24 h and the postnuclear supernatent was
analyzed directly or after streptavidin affinity purification.  Analysis of the starting
material demonstrated the stringent repression of A16 in the absence of IPTG (Figure
3-4A, Start). Importantly, the other EFC proteins examined, namely G9, A21 and L5,
were stable even in the absence of A16. Curiously, the faster migrating A56 band
predominated in the lysates of cells infected with vA16iA56TAPG93XFlag suggesting
initiation predominantly at the second start codon but this was independent of IPTG.
In the presence of IPTG, A56 interacted with K2, A16, G9, A21 and L5 as shown by
their copurification (Figure 3- 4A, Streptavidin). In contrast, only K2 interacted with
A56 when synthesis of A16 was repressed. Therefore, G9 cannot interact
independently with A56/K2.
 Recombinant vG9iA56TAP, which expressed an inducible form of G9 with an
HA epitope tag and TAP-tagged A56, was used to test whether A16 alone was able to
interact with A56/K2.  Western blotting showed that K2, A16, A28, A21, and
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Figure 3-4:  Both A16 and G9 are required for binding A56/K2.
(A) BS-C-1 cells were mock infected (M) or infected with VACV WR or
vA16iA56TAPG93xFlag (+ or – IPTG).  The cells were lysed with Triton X-100
after 24 h and the A56 protein was isolated by binding to streptavidin beads.  The
starting material (Start) and the affinity purified proteins (Streptavidin) were resolved
by SDS-PAGE and analyzed by Western blotting using antibodies to the viral
proteins indicated on the side. (B) HeLa cells were infected with vG9iHAA56TAP (+
and – IPTG) and the A56 protein was tandem affinity purified. The starting material
(Pre-TAP) and the purified proteins (TAP) were analyzed as in panel A.
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L5 co-purified with A56 when cells were infected in the presence of IPTG (Figure 3-
4B). However, only K2 co-purified with A56 when cells were infected in the absence
of IPTG. Because of the relatively weak signal produced by the antibody to A16, this
analysis was repeated in two independent experiments. With a more intense A16
signal in the +IPTG lane, a low amount of the protein was observed to co-purifying
with A56 when G9 was repressed. Therefore, both A16 and G9 are needed for
efficient interaction of either with A56/K2.
3.3.4 Association of A56/K2 with G9 requires A16.
Next, the reciprocal experiment was carried out to determine if A56/K2 co-
purified with Flag-tagged G9 in the absence of A16.  Cells were mock infected or
infected with VACV WR or vA16iA56TAPG93XFlag (+ and – IPTG). After 24 h, the G9
protein was purified from the postnuclear supernatent by incubating with the Flag
antibody conjugated to agarose beads. The beads were washed and the bound proteins
were eluted, separated by SDS-PAGE and analyzed by Western blotting. GAPDH
served as a control for loading and non-specific binding. Analysis of the lysate prior
to immunopurification confirmed the stringent control of A16 expression (Figure 3-5,
Start). When A16  was expressed (+ IPTG), the EFC represented by A28 and G9 as
well as A56 and K2 co-purified with G9 (Figure 3-5, Flag IP). When A16 synthesis
was repressed, however, A28, A56 or K2 failed to co-purified with G9. Therefore
A56/K2 did not stably bind to G9 in the absence of A16.
3.3.5 A16 and G9 stably associate with each other in uninfected cells.
The inability of G9 or A16 to independently associate with A56/K2 suggested
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Figure 3-5: A16 is required for G9 to bind A56/K2.
Cells were mock infected (M) or infected with VACV WR or vA16iA56TAPG93XFlag
(+ or – IPTG). Infected BS-C-1 cells were harvested at 24 h and lysed with Triton X-
100. Flag antibody conjugated to agarose beads was used to purify the G9 protein.
The bound material (Flag IP) was eluted from the agarose beads and separated along
with the starting material (Start) by SDS-PAGE and then transferred to nitrocellulose.
Western blotting was preformed using antibodies to the proteins A56, K2, A16, A28,
the Flag epitope or GAPDH as indicated.
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Figure 3-6: A16 and G9 interact in uninfected cells.
(A) 293TT cells were transfected with empty vector or plasmid DNA expressing A16
with a C-terminal influenza HA epitope (A16-HA) or co-transfected with plasmids
expressing A16-HA and G9 with a C-terminal 3XFlag tag (G9-Flag). After 48 h the
cells were lysed with Triton X-100, the postnuclear supernatant was incubated with
the Flag antibody bound to beads, and the captured proteins were analyzed by
Western blotting with the anti-HA antibody.  (B) Cells were transfected with empty
vector,  G9-Flag or co-transfected with A16-HA and G9-3XFlag.  The lysates were
incubated with anti-HA antibody bound to beads and the captured proteins were
analyzed by Western blotting with the anti-Flag antibody.
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these two EFC polypeptides existed as a heterodimer or higher order multimer. To
test this hypothesis, A16 and G9 were codon optimized for expression in human cells
and tagged with a C-terminal influenza HA epitope or a 3XFlag epitope, respectively.
A16HA and G93XFlag were cloned separately into pcDNA3.1 under control of the
human cytomegalovirus major immediate-early promoter. Human 293TT cells were
transfected with the individual plasmids or co-transfected with both. After 48 h, the
cells were lysed with Triton X-100 and synthesis of the recombinant proteins was
demonstrated by SDS-PAGE and Western blotting of portions of the postnuclear
supernatants (Figure 3-6A, Start; Figure 3-6B, Start). Additional portions of the
postnuclear supernatants were incubated with agarose conjugated to Flag or HA
antibody.  The beads were washed extensively and the eluted proteins analyzed by
SDS-PAGE and Western blotting. The A16HA protein was detected after the Flag
immunoprecipitation only when coexpressed with G93XFlag (Figure 3-6A, Flag IP).
Likewise, the G93XFlag was detected after the HA immunoprecipitation only when
coexpressed with A16HA (Figure 3-6B, HA IP). Thus, A16 and G9 can associate with
each other in the absence of other viral proteins.
3.4 Discussion
An unusual feature of VACV reproduction is that the infectious virus particles
are assembled in the cytoplasm, rather than at the plasma membrane, and
subsequently transported to the periphery and exocytosed.  Large numbers of progeny
virus particles remain adherent to the cell surface and these are chiefly responsible for
virus spread to neighboring cells [198]. It is believed that syncytia form when large
numbers of virus particles “fuse-back” i.e. deposit their fusion proteins into the
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plasma membrane of the parent cell. The fact that only small numbers of syncytia
form normally implies a negative regulation of fuse-back. The EV membrane
surrounding the MV may form one barrier to fuse-back, although MVs with broken
EV membranes are detected on the surface of cells [181]. The A56 and K2
polypeptides, which form a heteromultimer on the cell surface and EV membrane
may provide another barrier since a syncytial phenotype occurs with null mutants of
either [167-170, 172, 173]. It is possible A56/K2 could regulate fuse-back by
preventing the disruption of the EV membrane and exposure of the MV or the
subsequent interaction of the MV and plasma membranes. The ability of A56/K2 to
interact with the EFC suggests the latter mechanism is important although the EFC is
poorly characterized both structurally and functionally. In fact, it is not known
whether the EFC directly mediates fusion or is simply a positive regulator.
There are at least eight proteins within the EFC and numerous protein-protein
interactions are needed to form a stable complex [84]. To determine the binding
partners of A56/K2 individual proteins of the EFC were repressed to destabilize the
entry complex. Both A16 and G9 bound A56/K2, however alone these proteins
interacted weakly with A56/K2 suggesting that a complex of A16 and G9 is need for
the interaction with A56/K2. The interaction between A16 and G9 was confirmed by
coimmunoprecipitation of the two polypeptides following transfection of expression
vectors into uninfected cells. A model (Figure 3-7) depicts A56/K2 in the plasma
membrane of an infected cell interacting with A16 and G9 of the EFC in the viral
membrane.
78
A16 and G9 appear to have two roles. Each is required for membrane fusion
and virus entry as well as for interaction with A56/K2. Since viruses with mutations
in A56 or K2 form syncytia, it seemed possible that modifications of A16 or G9 that
perturb the interaction with A56/K2 could result in a similar phenotype.
In conclusion, the presence of A56/K2 in the plasma membrane provides a
way of differentiating infected from uninfected cells, presumably ensuring that
VACVs preferentially fuse with the latter.
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Figure 3-7:  Model by which A56/K2 inhibit infected cell fusion.
 G9 and A16 are anchored in MV membrane in association with EFC.  A56/K2 is
anchored in plasma membrane through the transmembrane domain of A56. The
interaction of A56/K2 with A16 and G9 is postulated to prevent fusion of the MV
particle with the plasma membrane. Fusion may be prevented as a resulting o f the
interaction of A56/K2 with the EFC which could prevent activation of the viral
fusion proteins.
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Chapter 4: Cells expressing A56 and K2 show reduced virus entry
and fusion with VACV infected cells
4.1 Introduction
In the absence of either A56 or K2 infected cells fuse spontaneously at neutral
pH [167-170, 172, 173].   A56 and K2 are regulators of cell-cell fusion, a process
thought to be the consequence of superinfection by cell surface EV [199].  In chapter
2 both A56 and K2 were shown to associate with proteins of the EFC.  A56 was
unable to bind the EFC in the absence of K2 and vice versa.  This suggested a
relationship between binding of A56/K2 to the EFC and inhibition of cell fusion.
Although the EFC is composed of at least eight proteins; only A16 and G9 were
important for interacting with A56/K2 (chapter 3).  Both A16 and G9 were needed to
interact with A56/K2 as neither protein alone bound efficiently.  A16 and G9
interacted in transfected cells independent of any additional viral proteins.  These data
support a model by which A56/K2 bind to the EFC to prevent infected cell fusion.
When cells are mixed after single infection with IHD-J (A56+) or IHD-W
(A56-) cell fusion occurs only between cells infected with IHD-W (A56-) [167].  To
provide support for a biological function for the interaction between A56/K2 and the
EFC cells expressing A56/K2, or each protein individually were mixed with cells
infected with v"A56"K2.  Cells expressing both A56 and K2 were resistant to fusion
compared to cells expressing A56 or K2 alone.   Expression of A56/K2 also
correlated with reduced virus entry.  These results strongly suggest A56/K2 inhibits
cell fusion and virus entry likely by interacting with the EFC.
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4.2 Material and Methods
4.2.1 Cells and virus.
BS-C-1 (ATCC CCL-26), HeLa S3 (ATCC CCL-2.2) suspension cells were
grown as described in chapter 2, section 2.2.1.  Growth of human 293TT cells was
described in chapter 3, section 3.2.1. Construction of v"A56"K2 was described in
chapter 2, section 2.3.  vFire-WR has been described previously in [94].   General
procedures for preparing and titrating stocks were done as previously described in
chapter 2, section 2.2.1.
4.2.2 Purification of VACV.
HeLa cells were infected at an MOI of 3 vFire-WR and incubated for 2 day at
37 
o
C.  VACV MV was isolated by mechanical disruption of HeLa S3 cells and
subjected to sedimentation twice through a 36% sucrose cushion.  Virus was
resuspended in 1mM Tris-HCl (pH 9.0) and titered as described in chapter 2, section
2.2.1.
4.2.3 Codon optimization of A56 and K2.
The DNA sequence for the VACV WR A56R and K2L genes was optimized
(Geneart, Regensburg, Germany) to improve RNA processing and translation by
altering codon usage and G-C content. The codon optimized A56R and K2L genes
were PCR amplified.   For A56, oligonucleotides were designed to append the DNA
sequence for a V5 epitope tag to the C terminus of the ORF. The PCR products of
A56V5 and K2 were cloned into the directional TOPO vector pcDNA 3.1 (Invitrogen)
and sequenced to confirm proper insertion and sequence.
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4.2.4 Transfection.
The day prior to transfection 2x10
5
 293TT cells were seeded per well of a 48
well plate in 300 !L of 10% DMEM lacking hygromycin.  A transfection mixture
was prepared as follows: 1.5 !L of Lipofectamine 2000 (Invitrogen) was mixed with
50 !L of Opti-Mem (Invitrogen) and incubated 5 min at room temperature.  In a
separate tube, 50 !L of Opti-Mem was combined with the DNA.  After 5 min the two
solutions were mixed and incubated a minimum of 25 min at room temperature.   The
different samples for transfection were configured as follows: 900 ng of total DNA,
100 ng of which is the P11-FFLUC plasmid that encodes the firefly luciferase gene
expressed from the late P11 viral promoter.  Cells were cotransfected with by adding
400 ng of A56 plasmid and 400 ng for K2.  Cells transfected with only a single
plasmid consisted of 400 ng of either A56, K2, or VSVG with the remaining 400 ng
of DNA supplemented with empty vector.  Once transfected the cells were grown for
24 h at 37 
o
C with 5% CO2 at which point the medium was changed and the cells
were incubated for an additional 24h prior to analysis.
4.2.5 Antibody staining and flow cytometry.
The following antibodies were used:  anti-A56 monoclonal antibody 1H831
(provided by Alan L Schmaljohn), anti-K2 monoclonal antibody 4A11-4A3 (provided
by Richard Moyer), Cy5-conjugated donkey anti-mouse. (Jackson ImmunoResearch).
Antibody staining was performed as follows: cells were resuspended and pelleted in
bench top centrifuge for 20 sec at 5k x g and supernatent was removed.  The primary
antibody (anti-A56 or anti-K2), diluted in 10% DMEM, was incubated with cells for
15 mins at which point the cells were washed twice with 500 !L DPBS without Ca
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and Mg (Quality Biological).  Secondary antibody (diluted 1:300 in 10% DMEM)
was incubated 15 min with the cells after which the cell were washed twice with 500
!L DPBS.  Samples were acquired on a FACSCalibur flow cytometer (BD
Immunocytometry Systems) and analyzed using FlowJo software (TreeStar, San
Carlos, CA).
4.2.6 Quantification of cell-cell fusion.
2x10
5
 BS-C-1 were seeded per well of 24 well plate.  The following day, cells
were infected at an MOI of 5 in 2.5% EMEM with v"A56"K2.  Separately, 293TT
cells were cotransfected with A56/K2 or transfected individually with A56, K2,
empty vector or the VSVG glycoprotein fused to GFP.  All transfections also
contained 100 ng of p11-FFluc plasmid.  After 48 h the transfected cells were
resuspended immediately prior to adding to the infected cell monolayer at a
concentration of 5x10
5
/mL in 10%DMEM with 40 !g cytosine arabinose (AraC).
The medium was removed from the infected cell monolayers at 18 h postinfection
and replaced with 250 !L of medium corresponding to 1.25x10
5
 293TT cells.  The
cells were incubated with the infected monolayer for 4 h at 37 
o
C and then lysed by
adding 100 !l of 3.5X cell culture lysis buffer (Promega).  Cells were incubated with
lysis buffer for 10 min at room temperature with constant rotation.  A 20 !l portion of
the lysate was mixed with 100 !l of luciferase assay substrate (Promega), and activity
was quantified on a Berthold Sirius luminometer.
4.2.7 Measuring virus entry
vFire-WR pelleted over 2X sucrose cushions was diluted in 10% DMEM to
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6x106 Pfu/ml.  50 µl of virus inoculum was added per well of a 48 well plate.  At 2 h
post-infection, medium was removed and cells were lysed by adding 100 µL of cell
culture lysis buffer and incubating 10 min at room temperature with constant rotation.
A 20 µl portion of lysate was removed and incubated with 100 µl of luciferase assay
substrate, Luc activity was quantified on a Berthold Sirius luminometer.
4.3 Results
4.3.1 Expression of A56 and K2 in transfected cells.
The A56 and K2 proteins localize to the plasma membrane of infected cells
and are also found in the EV membrane.  A56 is required for membrane retention of
K2 in both infected as well as transfected cells [173, 174].  A56 and K2 inhibit cell-
cell fusion possibly through an interaction with proteins of the EFC.  Cell surface
localization of A56 and K2 is important for inhibiting cell fusion which is supported
by studies which reveal: i) deletion of the membrane anchor of A56 [173], ii) deletion
of the signal sequence from K2 [174] or iii) addition of antibodies to A56 [172] and
K2 [173] lead to cell-cell fusion.
Cell surface localization of A56 and K2 was analyzed by flow cytometry.
Prior to expression in mammalian cells the A56 and K2 genes were codon optimized.
VACV genes are normally expressed in the cytoplasm and may contain sequences
inhibitory to nuclear expression.  The optimized A56 and K2 genes were individually
cloned into pcDNA3.1 under control of the human cytomegalovirus major
immediate-early promoter.  Cells were cotransfected with plasmids expressing A56
and K2, or with a single plasmid encoding A56, K2 or empty vector.  At 48 h post-
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Figure 4-1: Cell surface expression of A56 and K2.
293TT cells were cotransfected with plasmids expressing A56 and K2 (A, B), or
transfected  with a single plasmid for empty vector, A56 (C), or K2 (D).  At 48hr
posttransfection cells were stained with A56 antibody (A, C) or K2 antibody (B, D),
washed and incubated with secondary antibody conjugated to Cy5 prior to analysis by
flow cytometry.  Staining of cells transfected with empty vector is represented within
the gray shaded area.  Mean fluorescent intensity (MFI) is listed below the abscissa.
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transfection the cells were stained with antibodies to A56 or  K2, washed and then
stained with secondary antibodies conjugated with a fluorophore. Cells were not fixed
so as to retain the integrity of the plasma membrane and following staining the
samples were analyzed by flow cytometry.  Both the antibodies used to detect A56
and K2 were of mouse origin preventing simultaneously analysis of A56 and K2.
Instead, cells transfected with A56 and K2 were divided, with a portion stained with
A56 antibody and a portion with the K2 antibody.  Cells cotransfected with both A56
and K2 plasmid displayed abundant surface staining of both proteins (Figure 4-
1A+B).  Cells transfected with an A56 plasmid also exhibited extensive surface
staining for A56.  The gray area represents antibody staining of cells transfected with
empty vector.  The mean fluorescence intensity of cells expressing K2 alone was
reduced 7 fold when compared to cells expressing K2 with A56.  These results agree
well with previous reports that have demonstrated A56 is important for anchoring K2
to the plasma membrane [173].
4.3.2 A56/K2 expression correlates with reduced fusion with virus
induced syncytia.
Cell fusion occurs spontaneously at neutral pH among cells infected with
viruses that lack either the A56R or K2L gene.  If cells are mixed after single
infection with IHD-J (A56+) or IHD-W (A56-) cell fusion occurs only between cells
infected with IHD-W (A56-) [167].  This indicated acquisition of A56 was associated
with inhibiting cell fusion, but did not demonstrate A56 (along with K2) was
sufficient to inhibit cell fusion.
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To determine if A56 and K2 were sufficient to inhibit fusion, 293TT cells
were cotransfected with plasmids expressing A56 and K2, or transfected with a single
plasmid encoding A56, K2, VSVG glycoprotein fused to EGFP, or empty vector.  A
plasmid containing the firefly Luc gene under control of a late viral promoter was
included in all transfections to monitor cell fusion.  At 48 h post-transfection the cells
were resuspended in medium containing the viral DNA replication inhibitor AraC to
prevent virus late gene expression which may occur after the cells are mixed with the
infected monolayer.  The transfected 293TT cells were added to a monolayer of
BS-C-1 cells that had been infected 18 h previously with v"A56"K2.  Extensive cell
fusion had developed in the infected BS-C-1 monolayer by 18 h postinfection.  The
cells were incubated with the monolayer for 4 h, lysed and Luc activity was
measured.
Data is expressed as a ratio of the Luc activity relative to A56/K2.  Cells
expressing both A56 and K2 displayed the lowest Luc activity, which would be
expected if binding to the EFC inhibits fusion.  Comparing the Luc value of cells
expressing A56/K2 to the values obtained for cells expressing only A56 or K2
indicated a 3.72 and 5.53 fold increase in Luc activity, respectively, indicating cells
expressing only A56 or K2 were unable to inhibit fusion (Figure 4-2).  These data are
consistent A56 or K2 individually being unable to efficiently bind the EFC.  The ratio
of Luc value for cells expressing just A56 (3.72) was lower than the value obtained
from  cells expressing K2 alone (5.53) , VSVG (5.61) or empty vector (6.63),
however the value was well above what was observed for expression of A56/K2
(1.00). The VSVG glycoprotein and empty vector were used as negative controls
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Figure 4-2:  Effect of A56 and K2 expression on fusion between transfected cells
and VACV induced syncytia.
293TT cells were cotransfected with plasmids for A56 and K2 or transfected with a
single plasmid expressing A56, K2, VSVG or empty vector.  All transfections
included firefly luciferase plasmid as a reporter for cell-cell fusion.  At 48 h post-
transfection the cells were resuspended and added to a monolayer of BSC1 cells that
had been infected for 18 h with v"A56"K2.  After 4 hrs the cells were lysed and
assayed for firefly luciferase.  Data is represented as a ratio of relative light units
(RLU) relative to A56/K2 sample.  Experiments were preformed in quadruplicate and
data points represent the mean (listed below sample names) ± standard errors of the
means.
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 as cells transfected with either plasmid were not expected to inhibit cell fusion. A56
was observed to weakly interact with proteins of the EFC (Figure 2-5), which may
account for the slight reduction in Luc activity.  Never the less, optimal inhibition of
cell fusion required both A56 and K2. These results demonstrate that uninfected cells
are able to fuse with infected cells and cells expressing both A56 and K2 reduce the
extent of fusion.
4.3.3 A56 and K2 expression reduce virus infection.
 The processes of virus-cell fusion and cell-cell fusion require the conserved
multiprotein EFC, indicated A56/K2 may be able to regulate virus entry in addition to
cell-cell fusion.  There currently is no assay available to directly quantify virus
fusion, however early gene expression has been used to study entry of VACV.  The
VACV vFire-WR expresses the firefly Luc gene from an early-late promoter and Luc
synthesis begins almost immediate after virus entry. Although this is a post-fusion
assay it has been used previously to characterize the effect of low pH on virus entry
[94, 95].  293TT cells were cotransfected with plasmids for A56 and K2 or
transfected with a single plasmid for A56, K2, VSVG glycoprotein fused to GFP, or
empty vector.  At 48 h post-transfection cells were infected at an MOI of 1 with
vFire-WR, 2 h later the cells were lysed and the Luc activity was measured.
The data is reported as a ratio of Luc value compared to infection of cells
transfected with vector alone.  Cells transfected with both A56 and K2 displayed only
27% of the Luc activity of cells transfected with vector alone (Figure 4-3).  Cells
expressing only A56 or K2 failed to effectively inhibit virus entry to the extent of
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Figure 4-3:  Effect of A56 and K2 expression on VACV entry.
293TT cells were cotransfected with plasmids expressing A56 and K2 or transfected
with a single plasmid for A56, K2, VSVG or empty vector.  At 48hr post-transfection
cells were infected at an MOI of 1 with vFire-WR.  After 2hrs, luciferase activity was
measured and expressed as relative light units (RLU).  The data is the ratio of RLU
compared to vector.   Experiments were done in quadruplicate with the mean (listed
below the sample names) ± standard errors of the means.
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cells expressing both proteins.  In fact, cells expressing  K2 showed an increase in
Luc activity (1.57 fold), while a slight reduction in Luc expression was noted with
cells expressing A56 alone (68%) similar to what was noted for inhibition of cell-cell
fusion.  Cells expressing the VSVG glycoprotein displayed similar Luc activity (1.00)
compared to cells transfected with empty vector.  These results indicate that A56/K2
in addition to reducing cell-cell fusion also appear to reduce virus entry as measure by
early gene expression.
4.4 Discussion
Cell fusion is triggered by low pH treatment of infected cells [165, 166] or
occurs spontaneous at neutral pH with viruses that are deleted for A56R or K2L gene
[167-170, 172, 173].  Cell fusion depends on cell surface EV and is hypothesized to
involve “fuse back” of EV, in which the viral EFC is depositing into the plasma
membrane [199].  Viruses unable to form EV do not trigger cell fusion [152] and
fusion fails to occur when components of the viral EFC are repressed [80].  A56 and
K2 have been shown to bind the viral EFC.  This interaction was shown to depend on
expression of both A56 and K2 (chapter 2) and the fusion regulatory proteins
(A56/K2) were identified to interact specifically with A16 and G9 entry proteins
(chapter 3).  Through this interaction a model was developed by which A56/K2 binds
the EFC to inhibit cell-cell fusion (Figure 3-7).
Previous experiments involving mixing of cells individually infected with IHD-J
(A56+) or IHD-W (A56-) demonstrated cell fusion occurs only between cells infected
with IHD-W (A56-) [167].  In these experiments cells expressing A56 (and
presumably K2) were resistant to cell fusion.  To extend this observation and
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demonstrate A56/K2 are sufficient to prevent fusion, cells were transfected and
shown to express both A56 and K2 on their cell surface.  These cells were added to a
monolayer of cells that had formed syncytia and cell fusion was monitored by
activation of Luc.  Cells expressing both A56 and K2 fused poorly exhibiting only
20% of Luc activity relative to cells transfected with empty vector.  In comparison,
cells expressing only A56 or K2 were unable to inhibit cell fusion with Luc value 3.7
fold and 5.5 fold higher, respectively, compared to cells expressing A56/K2.  These
results were consistent with the inability of A56 or K2 alone to bind the EFC and
confirmed i) uninfected cells are able to fuse with syncytia form by infected cells and
ii) expression of A56 and K2 correlated with reduction in cell fusion with virus
triggered syncytia.  This provides the first evidence that A56 and K2 are sufficient to
inhibit cell fusion.    Cell-cell fusion and virus-cell fusion can be view as very similar
processes.  Entry of VACV was examined in cells expressing A56 and K2 by early
gene expression.   A56 and K2 reduced early gene expression by 70% compared to
cells transfected with empty vector.  Expression of A56 showed only a 30%
reduction, while K2 actually increased early gene expression.  The increase in Luc
expression observed for cells expressing K2 was unexpected.  Additional experiments
are required to explain the increase in Luc activity.  Perhaps the increase is related to
the SERPIN motif within K2.  A minor portion of A56 was observed to bind to the
EFC in the absence of K2, which may partially accounted for a slight reducing in
virus entry for cells expressing A56 (Figure 2-5).  These data offer the first evidence
for a biological significance to the interaction between A56/K2 and the EFC.
93
Chapter 5:  Conclusions and Future Direction
5.1 Conclusions
In this dissertation, I have sought to understand the mechanism by which A56
and K2 proteins inhibit infected cell-cell fusion.  Deletion of A56 or K2 is associated
with spontaneous neutral pH syncytia formation at late times during infection.
Spontaneous cell fusion requires EV and is likely mediated by superinfection of cell
surface EV.  Entry and fusion of VACV requires a conserved multiprotein complex
located within the MV membrane.
My dissertation project focused on identification of the protein interactions of
A56 and K2 related to the ability of these proteins to regulate infected cell fusion.
Tandem affinity purification revealed A56 interacted with proteins of the VACV
EFC.  A56 associates with K2 so it was conceivable that K2 may also bind the EFC.
An interaction between K2 and the EFC was confirmed by co-purification of the EFC
with the K2.  Further experiments revealed A56 failed to bind the EFC in the absence
of K2.  Interestingly, K2 displayed a similar dependence on A56 to bind the EFC.  To
validate an interaction between A56/K2 and the EFC the A28 protein was isolated by
tandem affinity purification and Western blot confirmed A56 and K2 associated with
the affinity purified EFC.  However, in the absence of K2, the A56 protein failed to
co-purify with the EFC.  The results reported in chapter 2 provided the first evidence
for an interaction between A56/K2 and the viral EFC.  More importantly, it suggested
binding of A56/K2 to the EFC might regulate infected cell fusion.  The inability of
A56 or K2 to bind the EFC independently agreed well with the requirement for both
proteins to inhibit cell fusion suggesting the two processes may be related.
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A56 is important for anchoring K2 to the plasma and EV membrane.  The two
proteins likely interact during transport through the secretory pathway, although the
domains involved in their interaction have not been well defined.  A region between
amino acids 145-373 of K2 is important for binding A56, while mutations that abolish
the protease inhibitory activity of K2 have no effect on interactions with A56 [173].
K2 with truncations of the N and C termini failed to inhibit cell fusion, suggesting
truncations may prevent the protein from assuming a particular conformation
important for regulating cell fusion.  In our hands, similar modifications of K2
generally eliminated the anti-fusion activity of the protein.
Neither the stoichiometry of the interaction between A56 and K2 nor whether
the two proteins are constantly associated is known.  Affinity purification of A56
identified a number of additional proteins that may compete with K2 for binding to
A56.  In particular the interaction between A56 and C3 could have potential benefit
for the virus in avoiding complement-mediated lysis of infected cells or virus
particles.
A direct interaction with the EFC could not be attributed to either A56 or K2
individually.  Perhaps the conformation of A56 and K2 is altered upon associating
with one another.  For example, binding of K2 with A56 may alter the conformation
of A56 and allow it to associate with the EFC, or the opposite may be true.
Alternatively, a conformation formed by the complex of A56/K2 may associate with
the EFC.  Still another possibility is that A56 and K2 both bind weakly to the EFC so
that a complex stable enough for isolation is only detected when the two are
associated. A minor form of A56 was observed to associate with the EFC even in the
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absence of K2 (Figure 2-5), suggesting A56 may directly bind the EFC.  Western blot
analysis of A56 indicates the protein migrates as multiple bands, likely related to
various states of glycosylation or alterative translation initiation.  Whether a particular
glycosylated form preferentially associates with K2 and the EFC was not addressed.
A soluble complex of A56 and K2 secreted from VACV infected cells was isolated
and shown to bind the EFC.  The higher molecular weight form of A56 predominated
in the soluble complex consistent with fully glycosylated protein being secreted from
the cell.  This high molecular weight species of A56 was sensitive to digestion with
proteinase K, indicating this form is likely present on the cell surface [172].  A56 and
K2 may also form higher oligomeric structures on the cell surface that could
potentially bind more efficiently to the viral EFC due to increased avidity.
Once it was identified that A56 and K2 interacted with the EFC the next step
was to determine which proteins within the EFC mediated the interaction.  Two
scenarios were considered: i) A56/K2 associates with the entire EFC, perhaps through
the interface formed by protein interactions within the complex, or alternatively ii)
individual proteins of the EFC interact directly with A56/K2.  The viral EFC is
composed of at least eight proteins.  To determine which of these the protein were
important for binding A56/K2, a series of conditional lethal viruses were constructed.
The viral EFC has been shown not to form when synthesis of A21 or A28 is repressed
[84].  Affinity purification of A56 in the absence of either A21 or A28 revealed
interactions with the EFC were limited to A16 and G9.  This suggested that only a
subset of the EFC was required to interact with A56/K2.
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Since both A16 and G9 co-purified with A56/K2 it was unknown which of the
two proteins directly mediated the interaction.  To assess this, synthesis of A16 or G9
was repressed and affinity purification of A56/K2 was performed.  In the absence of
A16, the G9 protein did not associate with A56/K2, while in the absence of G9, the
A16 protein did not co-purified with A56/K2.  The co-purification of G9 and A16
with A56/K2 suggested a direct association between A16 and G9.  This was further
supported by the inability of either A16, or G9 to bind individually to A56/K2.  To
investigate the potential interaction between A16 and G9 the two proteins were
expressed by transfection in uninfected cells.  A16 immunoprecipitated G9, and A16
was shown to co-purified with G9.  This result was the first to demonstrate an
interaction between two proteins of the EFC.  An interaction between H2 and A28
has been inferred, due in part to the ability of the two proteins to associate in the
absence of A16, although the proteins had not yet been shown to interact in the
absence of a virus infection [84].  A current focus of the lab is to identify additional
protein interaction within the viral EFC.
The identification and characterization of an interaction between the EFC and
A56/K2 was important for understanding the mechanism for regulation of cell fusion,
however biological significance for this interaction still remained to be established.
The working hypothesis is cells expressing A56 and K2 may be refractory to cell-cell
fusion or infection.  A56/K2 are predicted to interact with the EFC at the cell surface.
Therefore, cells transfected with A56 and K2 were monitored for surface expression
of the two proteins by flow cytometry.  Both A56 and K2 localized to the surface of
transfected cells.  In the absence of A56, a significant decrease was observed in the
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amount of cell surface K2, consistent with the requirement of A56 for retention of K2
on the plasma membrane.  Therefore the A56 and K2 proteins behave normally in
these transfected cells.
Cells infected with v"A56"K2 normally exhibit extensive cell fusion.  Our
thought was thatcells transfected with A56/K2 would exhibit resistance to fusing with
the syncytia in much the same way that cells infected with wild-type virus expressing
A56/K2 do not fuse with A56 negative infected cells.  Indeed, cells transfected with
A56/K2 displayed greatly reduced fusion with the syncytia monolayer (as monitored
by Luc activity) compared to cells transfected with an empty vector.  In comparison,
cells expressing either A56 alone or K2 alone had a 3 to 5 fold increase, respectively,
in Luc activity compared to cells expressing both A56/K2.  This was consistent with
the requirement of A56/K2 to bind the EFC.  Expression of A56 and K2 did not
eliminate the ability of the cell to fuse with the syncytia, but significantly reduced the
amount fusion.
The process of cell-cell fusion and virus-cell fusion both depend on the viral
EFC.  Since expression of A56/K2 reduced fusion of cells with the syncytia, the
infectivity of cells expressing A56/K2 may also be reduced.  To test this, cells were
infected with a VACV expressing the Luc gene to measure virus entry.  Cells
expressing both A56/K2 displayed a dramatic reduction in Luc activity compared to
cells transfected with vector alone.  This indicates cells expressing A56/K2 display a
reduction in fusion with syncytia and entry of VACV.
There is no obvious benefit gained by superinfection of cells indicating the
ability to regulate infected cell fusion may offer several advantages to the VACV.
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Expression of A56/K2 may aid the virus in distinguishing between infected and
uninfected cells.  Alternatively, the development of large multinucleated syncytia
may lead to premature apoptosis.  Other viruses, notably HIV and influenza virus,
have mechanisms to prevent superinfection by either downregulating or removal of
cell proteins important for initiating virus entry and infection.  Certain strains of
herpesvirus are known to form syncytia in cell culture.  Syncytia formation is
associated with mutations the viral glycoproteins gK [200] and gB [201] as well as
mutations in UL20 [202].   The mechanisms by which the mutations inhibit cell-cell
fusion are unknown, perhaps these mutations alter trafficking or enhance surface
expression of the viral fusion proteins.  It has been proposed that syncytia formation
in herpesviruses may be detrimental to the virus in vivo [203].
In conclusion, the A56 and K2 proteins are required for inhibition of infected
cell fusion.  Affinity purification of A56 and K2 identified an interaction with the
viral EFC, suggesting this association may be important for inhibition of infected cell
fusion.  Cells expressing A56 and K2 were resistant to fusion with virus induced
syncytia and displayed a similar resistance to virus entry.  Additional studies should
reveal the mechanism by which binding of A56/K2 to A16/G9 inhibit virus fusion.
5.2 Future Directions
Identification and characterization of the interaction between A56/K2 and the
EFC provides the first evidence for a molecular mechanism for the regulation of
infected cell fusion.  Much remains to be determined with respect to poxvirus entry
and fusion, in particular how the interaction of A56/K2 with the EFC regulates cell-
cell fusion.  Although the EFC is required for virus-cell and cell-cell fusion it is
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uncertain whether the EFC directly mediates fusion or has an accessory role, perhaps
serving as a scaffold for assembly of the fusion protein(s).   Never the less, VACV
appears to have evolved a mechanism of regulating cell fusion through the interaction
of A56/K2 with EFC.
Antibodies to A56 and K2 trigger cell fusion similar to deletion of the
respective protein.  The antibodies may trigger cell fusion through several
mechanism:  i) the antibodies disrupt interactions between A56/K2 and the EFC or ii)
the antibodies trigger endocytosis of A56 or K2, down regulating surface expression.
The former is the more interesting outcome as the antibody epitopes could be mapped
to identify domains within A56 and K2 important for the interaction with the EFC.
 A cell line expressing A56 and K2 would be preferred over transfection,
which is associated with variation in the number of cells transfected as well as the
level of protein expression.  A cell line expressing A56 and K2 would be anticipated
to display a similar inhibition of virus entry as transfection and could be used to
screen for viral mutants.  In particular, viral mutants that trigger cell fusion in the
presence of A56/K2 or are unable to bind the fusion regulatory proteins may be
identified.  Alternatively, a soluble complex of A56 and K2, at a high enough
concentration, may inhibit virus entry and provide a means of identifying viral
mutants resistant to the anti-fusion activity of A56/K2.
VACV has evolved a mechanism for regulation of cell fusion facilitated by
interaction with A56/K2.  This indicates A16 and G9 may represent a novel target for
development of antipoxvirus agents.  A better understanding of the interactions of
A16/G9 with other proteins within the EFC may shed light on a mechanism by which
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A56/K2 inhibit cell-cell fusion leading to development of small molecule inhibitors
of virus entry.
Neutral pH cell fusion caused by deletion of A56 and K2 is likely mediated by
superinfection of cell surface EV, although direct evidence is lacking.  Electron
microscopy has been utilized to examine entry of VACV and images have been
captured documenting fusion of both MV [91-93] and EV [97] particles with the cell
membrane.  It may be difficult to capture the presumably rare asynchronous fuse back
of EV, however during the course of superinfection the MV membrane merges with
the plasma membrane.  Therefore, immunoelectron microscopy could be used to
examine the plasma membrane for an increase in MV proteins when cells are infected
with an A56 or K2 deletion virus.
Many additional questions with regard to A56/K2 regulation remain to be
answered, for example. What is the stoichiometry of the interaction between A56/K2?
Is glycosylation of A56 important for binding A16/G9?  What components of the
EFC do A16 and G9 associate with?  How does binding of A56/K2 to A16/G9 inhibit
fusion (steric hindrance)?  How is the EFC involved in virus fusion?  Deletion of A56
and K2 is associated with cell-cell fusion in cell culture, but does cell-cell fusion
occur in vivo?  Are there additional mechanisms for inhibiting superinfection?  A56
and K2 are primarily expressed during late gene expression, suggesting there may be
an additional mechanism for preventing superinfection during early and intermediate
gene expression.   If this is the case, why are these mechanisms unable to prevent EV
superinfection?
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Finally, the work that I have presented in this dissertation has provided a
foundation to better understand the mechanism by which VACV regulates infected
cell fusion.  Hopefully, the questions I have addressed over the course of my research
have provided the poxvirus field with information needed to further examine the
mechanism of virus entry and fusion.
102
Bibliography
1. Esposito, L.J. and F. Fenner, Poxviruses, in Fields Virology, D.M. Knipe and
P.M. Howley, Editors. 2001, Lippincott Williams & Wilkins: Philadelphia. p.
2885-2921.
2. Jenner, E., An inquiry into the causes and effects of the variolae vaccinae, a
disease discovered in some of the western countries of England, particularly
near Gloucestershire, and known by the name of the cow pox, London, in
reprinted in Classics of Medicine and Surgery, 1959, C.N.B. Camac, Editor.
1798, Dover: New York. p. 213-240.
3. Moss, B., Poxviridae: The viruses and their replication, in Fields Virology,
D.M. Knipe, et al., Editors. 2007, Lippincott Williams & Wilkins:
Philadelphia. p. 2905-2946.
4. Gubser, C., et al., Poxvirus genomes: a phylogenetic analysis. J Gen Virol,
2004. 85(Pt 1): p. 105-17.
5. Goebel, S.J., et al., The complete DNA sequence of vaccinia virus. Virology,
1990. 179(1): p. 247-66, 517-63.
6. Gangemi, J.D. and D.G. Sharp, Use of a restriction endonuclease in analyzing
the genomes from two different strains of vaccinia virus. J Virol, 1976. 20(1):
p. 319-23.
7. McCarron, R.J., et al., Structure of vaccinia DNA: analysis of the viral
genome by restriction endonucleases. Virology, 1978. 86(1): p. 88-101.
8. Garon, C.F., E. Barbosa, and B. Moss, Visualization of an inverted terminal
repetition in vaccinia virus DNA. Proc Natl Acad Sci U S A, 1978. 75(10): p.
4863-7.
9. Wittek, R., et al., Inverted terminal repeats in rabbit poxvirus and vaccinia
virus DNA. J. Virol., 1978. 28: p. 171-181.
10. Wittek, R. and B. Moss, Tandem repeats within the inverted terminal
repetition of vaccinia virus DNA. Cell, 1980. 21(1): p. 277-84.
11. Baroudy, B.M., S. Venkatesan, and B. Moss, Incompletely base-paired flip-
flop terminal loops link the two DNA strands of the vaccinia virus genome
into one uninterrupted polynucleotide chain. Cell, 1982. 28(2): p. 315-24.
12. DeLange, A.M., et al., Replication and resolution of cloned poxvirus
telomeres in vivo generates linear minichromosomes with intact viral hairpin
termini. J Virol, 1986. 59(2): p. 249-59.
13. Merchlinsky, M. and B. Moss, Resolution of linear minichromosomes with
hairpin ends from circular plasmids containing vaccinia virus concatemer
junctions. Cell, 1986. 45(6): p. 879-84.
14. DeLange, A.M. and G. McFadden, Efficient resolution of replicated poxvirus
telomeres to native hairpin structures requires two inverted symmetrical
copies of a core target DNA sequence. J Virol, 1987. 61(6): p. 1957-63.
15. Merchlinsky, M. and B. Moss, Nucleotide sequence required for resolution of
the concatemer junction of vaccinia virus DNA. J Virol, 1989. 63(10): p.
4354-61.
103
16. Smith, G.L., A. Vanderplasschen, and M. Law, The formation and function of
extracellular enveloped vaccinia virus. J Gen Virol, 2002. 83(Pt 12): p. 2915-
31.
17. Ward, B.M., The longest micron; transporting poxviruses out of the cell. Cell
Microbiol, 2005. 7(11): p. 1531-8.
18. Cyrklaff, M., et al., Cryo-electron tomography of vaccinia virus. Proc Natl
Acad Sci U S A, 2005. 102(8): p. 2772-7.
19. Malkin, A.J., A. McPherson, and P.D. Gershon, Structure of intracellular
mature vaccinia virus visualized by in situ atomic force microscopy. Journal
of Virology, 2003. 77(11): p. 6332-6340.
20. Dubochet, J., et al., Structure of intracellular mature vaccinia virus observed
by cryoelectron microscopy. J Virol, 1994. 68(3): p. 1935-41.
21. Hollinshead, M., et al., Vaccinia virus intracellular mature virions contain
only one lipid membrane. J Virol, 1999. 73(2): p. 1503-17.
22. Dales, S. and E.H. Mosbach, Vaccinia as a model for membrane biogenesis.
Virology, 1968. 35(4): p. 564-83.
23. Griffiths, G., et al., Structure and assembly of intracellular mature vaccinia
virus: isolated-particle analysis. J Virol, 2001. 75(22): p. 11034-55.
24. Roos, N., et al., A novel immunogold cryoelectron microscopic approach to
investigate the structure of the intracellular and extracellular forms of
vaccinia virus. EMBO Journal, 1996. 15(10): p. 2343-2355.
25. Sodeik, B., et al., Assembly of vaccinia virus: role of the intermediate
compartment between the endoplasmic reticulum and the Golgi stacks. J Cell
Biol, 1993. 121(3): p. 521-41.
26. Oie, M. and Y. Ichihashi, Characterization of vaccinia polypeptides.
Virology, 1981. 113(1): p. 263-76.
27. Essani, K. and S. Dales, Biogenesis of vaccinia: evidence for more than 100
polypeptides in the virion. Virology, 1979. 95(2): p. 385-94.
28. Chung, C.S., et al., Vaccinia virus proteome: identification of proteins in
vaccinia virus intracellular mature virion particles. J Virol, 2006. 80(5): p.
2127-40.
29. Yoder, J.D., et al., Pox proteomics: mass spectrometry analysis and
identification of Vaccinia virion proteins. Virol J, 2006. 3: p. 10.
30. Resch, W., et al., Protein composition of the vaccinia virus mature virion.
Virology, 2007. 358(1): p. 233-47.
31. Moss, B., et al., Cytoplasmic transcription system encoded by vaccinia virus. J
Biol Chem, 1991. 266(3): p. 1355-8.
32. Jones, E.V., C. Puckett, and B. Moss, DNA-dependent RNA polymerase
subunits encoded within the vaccinia virus genome. J Virol, 1987. 61(6): p.
1765-71.
33. Broyles, S.S. and B. Moss, Sedimentation of an RNA polymerase complex
from vaccinia virus that specifically initiates and terminates transcription.
Mol Cell Biol, 1987. 7(1): p. 7-14.
34. Martin, S.A., E. Paoletti, and B. Moss, Purification of mRNA
guanylyltransferase and mRNA(guanine 7) methyltransferase from vaccinia
virions. Journal of Biological Chemistry, 1975. 250(24): p. 9322-9329.
104
35. Morgan, J.R., L.K. Cohen, and B.E. Roberts, Identification of the DNA
sequences encoding the large subunit of the mRNA-capping enzyme of
vaccinia virus. J Virol, 1984. 52(1): p. 206-14.
36. Niles, E.G., et al., Vaccinia virus gene D12L encodes the small subunit of the
viral mRNA capping enzyme. Virology, 1989. 172(2): p. 513-22.
37. Moss, B., E.N. Rosenblum, and A. Gershowitz, Characterization of a
polyriboadenylate polymerase from vaccinia virions. J Biol Chem, 1975.
250(12): p. 4722-9.
38. Broyles, S.S. and B.S. Fesler, Vaccinia virus gene encoding a component of
the viral early transcription factor. J Virol, 1990. 64(4): p. 1523-9.
39. Gershon, P.D. and B. Moss, Early transcription factor subunits are encoded
by vaccinia virus late genes. Proc Natl Acad Sci U S A, 1990. 87(11): p.
4401-5.
40. Rosales, R., et al., Purification and identification of a vaccinia virus-encoded
intermediate stage promoter-specific transcription factor that has homology
to eukaryotic transcription factor SII (TFIIS) and an additional role as a viral
RNA polymerase subunit. J Biol Chem, 1994. 269(19): p. 14260-7.
41. Rosales, R., G. Sutter, and B. Moss, A cellular factor is required for
transcription of vaccinia viral intermediate-stage genes. Proc Natl Acad Sci U
S A, 1994. 91(9): p. 3794-8.
42. Sanz, P. and B. Moss, A new vaccinia virus intermediate transcription factor.
J Virol, 1998. 72(8): p. 6880-3.
43. Sanz, P. and B. Moss, Identification of a transcription factor, encoded by two
vaccinia virus early genes, that regulates the intermediate stage of viral gene
expression. Proc Natl Acad Sci U S A, 1999. 96(6): p. 2692-7.
44. Keck, J.G., C.J. Baldick, Jr., and B. Moss, Role of DNA replication in
vaccinia virus gene expression: a naked template is required for transcription
of three late trans-activator genes. Cell, 1990. 61(5): p. 801-9.
45. Parrish, S. and B. Moss, Characterization of a second vaccinia virus mRNA-
decapping enzyme conserved in poxviruses. J Virol, 2007. 81(23): p. 12973-8.
46. Parrish, S. and B. Moss, Characterization of a vaccinia virus mutant with a
deletion of the D10R gene encoding a putative negative regulator of gene
expression. J Virol, 2006. 80(2): p. 553-61.
47. Parrish, S., W. Resch, and B. Moss, Vaccinia virus D10 protein has mRNA
decapping activity, providing a mechanism for control of host and viral gene
expression. Proc Natl Acad Sci U S A, 2007. 104(7): p. 2139-44.
48. Senkevich, T.G., A.S. Weisberg, and B. Moss, Vaccinia virus E10R protein is
associated with the membranes of intracellular mature virions and has a role
in morphogenesis. Virology, 2000. 278(1): p. 244-252.
49. Senkevich, T.G., et al., Expression of the vaccinia virus A2.5L redox protein
is required for virion morphogenesis. Virology, 2002. 300(2): p. 296-303.
50. White, C.L., A.S. Weisberg, and B. Moss, A glutaredoxin, encoded by the
G4L gene of vaccinia virus, is essential for virion morphogenesis. Journal of
Virology, 2000. 74(19): p. 9175-9183.
105
51. White, C.L., T.G. Senkevich, and B. Moss, Vaccinia virus G4L glutaredoxin
is an essential intermediate of a cytoplasmic disulfide bond pathway required
for virion assembly. J Virol, 2002. 76(2): p. 467-72.
52. Senkevich, T.G., et al., A viral member of the ERV1/ALR protein family
participates in a cytoplasmic pathway of disulfide bond formation. Proc Natl
Acad Sci U S A, 2000. 97(22): p. 12068-73.
53. Senkevich, T.G., et al., Complete pathway for protein disulfide bond
formation encoded by poxviruses. Proc Natl Acad Sci U S A, 2002. 99(10): p.
6667-72.
54. Seet, B.T., et al., Poxviruses and immune evasion. Annu Rev Immunol, 2003.
21: p. 377-423.
55. Johnston, J.B. and G. McFadden, Poxvirus immunomodulatory strategies:
current perspectives. J Virol, 2003. 77(11): p. 6093-100.
56. Langland, J.O. and B.L. Jacobs, The role of the PKR-inhibitory genes, E3L
and K3L, in determining vaccinia virus host range. Virology, 2002. 299(1): p.
133-41.
57. Chang, H.W. and B.L. Jacobs, Identification of a conserved motif that is
necessary for binding of the vaccinia virus E3L gene products to double-
stranded RNA. Virology, 1993. 194(2): p. 537-47.
58. Kotwal, G.J. and B. Moss, Vaccinia virus encodes a secretory polypeptide
structurally related to complement control proteins. Nature, 1988. 335(6186):
p. 176-8.
59. Kotwal, G.J., et al., Inhibition of the complement cascade by the major
secretory protein of vaccinia virus. Science, 1990. 250(4982): p. 827-30.
60. Jackson, S.S., et al., Role of genes that modulate host immune responses in the
immunogenicity and pathogenicity of vaccinia virus. J Virol, 2005. 79(10): p.
6554-9.
61. Lackner, C.A., et al., Complementation analysis of the dales collection of
vaccinia virus temperature-sensitive mutants. Virology, 2003. 305(2): p. 240-
59.
62. Punjabi, A., et al., Clustered charge-to-alanine mutagenesis of the vaccinia
virus A20 gene: temperature-sensitive mutants have a DNA-minus phenotype
and are defective in the production of processive DNA polymerase activity. J
Virol, 2001. 75(24): p. 12308-18.
63. da Fonseca, F.G., et al., Vaccinia virus mutants with alanine substitutions in
the conserved G5R gene fail to initiate morphogenesis at the nonpermissive
temperature. J Virol, 2004. 78(19): p. 10238-48.
64. Fuerst, T.R., M.P. Fernandez, and B. Moss, Transfer of the inducible lac
repressor/operator system from Escherichia coli to a vaccinia virus
expression vector. Proc Natl Acad Sci U S A, 1989. 86(8): p. 2549-53.
65. Traktman, P., et al., Elucidating the essential role of the A14 phosphoprotein
in vaccinia virus morphogenesis: construction and characterization of a
tetracycline-inducible recombinant. J Virol, 2000. 74(8): p. 3682-95.
66. Alexander, W.A., B. Moss, and T.R. Fuerst, Regulated expression of foreign
genes in vaccinia virus under the control of bacteriophage T7 RNA
106
polymerase and the Escherichia coli lac repressor. J Virol, 1992. 66(5): p.
2934-42.
67. Chahroudi, A., et al., Vaccinia virus tropism for primary hematolymphoid
cells is determined by restricted expression of a unique virus receptor. J Virol,
2005. 79(16): p. 10397-407.
68. Chang, W., et al., Isolation of a monoclonal antibody which blocks vaccinia
virus infection. J Virol, 1995. 69(1): p. 517-22.
69. Niles, E.G. and J. Seto, Vaccinia virus gene D8 encodes a virion
transmembrane protein. Journal of Virology, 1988. 62(10): p. 3772-3778.
70. da Fonseca, F.G., et al., Effects of deletion or stringent repression of the H3L
envelope gene on vaccinia virus replication. J Virol, 2000. 74(16): p. 7518-28.
71. Senkevich, T.G. and B. Moss, Vaccinia virus H2 protein is an essential
component of a complex involved in virus entry and cell-cell fusion. J Virol,
2005. 79(8): p. 4744-54.
72. Ward, B.M., Visualization and characterization of the intracellular movement
of vaccinia virus intracellular mature virions. J Virol, 2005. 79(8): p. 4755-
63.
73. Chung, C.S., et al., A27L protein mediates vaccinia virus interaction with cell
surface heparan sulfate. J Virol, 1998. 72(2): p. 1577-85.
74. Hsiao, J.C., C.S. Chung, and W. Chang, Vaccinia virus envelope D8L protein
binds to cell surface chondroitin sulfate and mediates the adsorption of
intracellular mature virions to cells. J Virol, 1999. 73(10): p. 8750-61.
75. Lin, C.L., et al., Vaccinia virus envelope H3L protein binds to cell surface
heparan sulfate and is important for intracellular mature virion
morphogenesis and virus infection in vitro and in vivo. J Virol, 2000. 74(7): p.
3353-65.
76. Chiu, W.L., et al., Vaccinia virus 4c (A26L) protein on intracellular mature
virus binds to the extracellular cellular matrix laminin. J Virol, 2007. 81(5):
p. 2149-57.
77. Chung, C.S., C.Y. Huang, and W. Chang, Vaccinia virus penetration requires
cholesterol and results in specific viral envelope proteins associated with lipid
rafts. J Virol, 2005. 79(3): p. 1623-34.
78. Ojeda, S., T.G. Senkevich, and B. Moss, Entry of vaccinia virus and cell-cell
fusion require a highly conserved cysteine-rich membrane protein encoded by
the A16L gene. J Virol, 2006. 80(1): p. 51-61.
79. Townsley, A.C., T.G. Senkevich, and B. Moss, Vaccinia virus A21 virion
membrane protein is required for cell entry and fusion. J Virol, 2005. 79(15):
p. 9458-69.
80. Senkevich, T.G., B.M. Ward, and B. Moss, Vaccinia virus entry into cells is
dependent on a virion surface protein encoded by the A28L gene. J Virol,
2004. 78(5): p. 2357-66.
81. Townsley, A.C., T.G. Senkevich, and B. Moss, The product of the vaccinia
virus L5R gene is a fourth membrane protein encoded by all poxviruses that is
required for cell entry and cell-cell fusion. J Virol, 2005. 79(17): p. 10988-98.
82. Izmailyan, R.A., et al., The envelope G3L protein is essential for entry of
vaccinia virus into host cells. J Virol, 2006. 80(17): p. 8402-10.
107
83. Ojeda, S., A. Domi, and B. Moss, Vaccinia virus G9 protein is an essential
component of the poxvirus entry-fusion complex. J Virol, 2006. 80(19): p.
9822-30.
84. Senkevich, T.G., et al., Poxvirus multiprotein entry-fusion complex. Proc Natl
Acad Sci U S A, 2005. 102(51): p. 18572-7.
85. Senkevich, T.G., B.M. Ward, and B. Moss, Vaccinia virus A28L gene encodes
an essential protein component of the virion membrane with intramolecular
disulfide bonds formed by the viral cytoplasmic redox pathway. J Virol, 2004.
78(5): p. 2348-56.
86. Wolffe, E.J., S. Vijaya, and B. Moss, A myristylated membrane protein
encoded by the vaccinia virus L1R open reading frame is the target of potent
neutralizing monoclonal antibodies. Virology, 1995. 211(1): p. 53-63.
87. Rodriguez, J.F., E. Paez, and M. Esteban, A 14,000-Mr envelope protein of
vaccinia virus is involved in cell fusion and forms covalently linked trimers. J
Virol, 1987. 61(2): p. 395-404.
88. Rodriguez, J.F., R. Janeczko, and M. Esteban, Isolation and characterization
of neutralizing monoclonal antibodies to vaccinia virus. J Virol, 1985. 56(2):
p. 482-8.
89. Ravanello, M.P. and D.E. Hruby, Conditional lethal expression of the
vaccinia virus L1R myristylated protein reveals a role in virion assembly. J
Virol, 1994. 68(10): p. 6401-10.
90. Brown, E., T.G. Senkevich, and B. Moss, Vaccinia virus F9 virion membrane
protein is required for entry but not virus assembly, in contrast to the related
L1 protein. J Virol, 2006. 80(19): p. 9455-64.
91. Carter, G.C., et al., Entry of the vaccinia virus intracellular mature virion and
its interactions with glycosaminoglycans. J Gen Virol, 2005. 86(Pt 5): p.
1279-90.
92. Chang, A. and D.H. Metz, Further investigations on the mode of entry of
vaccinia virus into cells. J Gen Virol, 1976. 32(2): p. 275-82.
93. Armstrong, J.A., D.H. Metz, and M.R. Young, The mode of entry of vaccinia
virus into L cells. J Gen Virol, 1973. 21(3): p. 533-7.
94. Townsley, A.C., et al., Vaccinia virus entry into cells via a low-pH-dependent
endosomal pathway. J Virol, 2006. 80(18): p. 8899-908.
95. Townsley, A.C. and B. Moss, Two distinct low-pH steps promote entry of
vaccinia virus. J Virol, 2007. 81(16): p. 8613-20.
96. Vanderplasschen, A., M. Hollinshead, and G.L. Smith, Intracellular and
extracellular vaccinia virions enter cells by different mechanisms. J Gen
Virol, 1998. 79 ( Pt 4): p. 877-87.
97. Law, M., et al., Ligand-induced and nonfusogenic dissolution of a viral
membrane. Proc Natl Acad Sci U S A, 2006. 103(15): p. 5989-94.
98. Carter, G.C., et al., Vaccinia virus cores are transported on microtubules. J
Gen Virol, 2003. 84(Pt 9): p. 2443-58.
99. Holowczak, J.A., Uncoating of poxviruses. I. Detection and characterization
of subviral particles in the uncoating process. Virology, 1972. 50(1): p. 216-
32.
108
100. Moss, B., Regulation of vaccinia virus transcription. Annu Rev Biochem,
1990. 59: p. 661-88.
101. Paoletti, E. and L.J. Grady, Transcriptional complexity of vaccinia virus in
vivo and in vitro. J Virol, 1977. 23(3): p. 608-15.
102. Boone, R.F. and B. Moss, Sequence complexity and relative abundance of
vaccinia virus mRNA's synthesized in vivo and in vitro. J Virol, 1978. 26(3): p.
554-69.
103. Katsafanas, G.C. and B. Moss, Vaccinia virus intermediate stage transcription
is complemented by Ras-GTPase-activating protein SH3 domain-binding
protein (G3BP) and cytoplasmic activation/proliferation-associated protein
(p137) individually or as a heterodimer. J Biol Chem, 2004. 279(50): p.
52210-7.
104. Katsafanas, G.C. and B. Moss, Colocalization of transcription and translation
within cytoplasmic poxvirus factories coordinates viral expression and
subjugates host functions. Cell Host Microbe, 2007. 2(4): p. 221-8.
105. Keck, J.G., G.R. Kovacs, and B. Moss, Overexpression, purification, and late
transcription factor activity of the 17-kilodalton protein encoded by the
vaccinia virus A1L gene. J Virol, 1993. 67(10): p. 5740-8.
106. Passarelli, A.L., G.R. Kovacs, and B. Moss, Transcription of a vaccinia virus
late promoter template: requirement for the product of the A2L intermediate-
stage gene. J Virol, 1996. 70(7): p. 4444-50.
107. Zhang, Y., J.G. Keck, and B. Moss, Transcription of viral late genes is
dependent on expression of the viral intermediate gene G8R in cells infected
with an inducible conditional-lethal mutant vaccinia virus. J Virol, 1992.
66(11): p. 6470-9.
108. Kovacs, G.R. and B. Moss, The vaccinia virus H5R gene encodes late gene
transcription factor 4: purification, cloning, and overexpression. J Virol,
1996. 70(10): p. 6796-802.
109. Davison, A.J. and B. Moss, Structure of vaccinia virus early promoters. J Mol
Biol, 1989. 210(4): p. 749-69.
110. Davison, A.J. and B. Moss, Structure of vaccinia virus late promoters. J Mol
Biol, 1989. 210(4): p. 771-84.
111. Baldick, C.J., Jr., J.G. Keck, and B. Moss, Mutational analysis of the core,
spacer, and initiator regions of vaccinia virus intermediate-class promoters. J
Virol, 1992. 66(8): p. 4710-9.
112. Wright, C.F. and B. Moss, In vitro synthesis of vaccinia virus late mRNA
containing a 5' poly(A) leader sequence. Proc Natl Acad Sci U S A, 1987.
84(24): p. 8883-7.
113. Ahn, B.Y. and B. Moss, Capped poly(A) leaders of variable lengths at the 5'
ends of vaccinia virus late mRNAs. J Virol, 1989. 63(1): p. 226-32.
114. Ink, B.S. and D.J. Pickup, Vaccinia virus directs the synthesis of early mRNAs
containing 5' poly(A) sequences. Proc Natl Acad Sci U S A, 1990. 87(4): p.
1536-40.
115. Yuen, L. and B. Moss, Oligonucleotide sequence signaling transcriptional
termination of vaccinia virus early genes. Proc Natl Acad Sci U S A, 1987.
84(18): p. 6417-21.
109
116. Shuman, S. and B. Moss, Factor-dependent transcription termination by
vaccinia virus RNA polymerase. Evidence that the cis-acting termination
signal is in nascent RNA. J Biol Chem, 1988. 263(13): p. 6220-5.
117. Mahr, A. and B.E. Roberts, Arrangement of late RNAs transcribed from a 7.1-
kilobase EcoRI vaccinia virus DNA fragment. J Virol, 1984. 49(2): p. 510-20.
118. Cooper, J.A., R. Wittek, and B. Moss, Extension of the transcriptional and
translational map of the left end of the vaccinia virus genome to 21 kilobase
pairs. J Virol, 1981. 39(3): p. 733-45.
119. Antczak, J.B., et al., Site-specific RNA cleavage generates the 3' end of a
poxvirus late mRNA. Proc Natl Acad Sci U S A, 1992. 89(24): p. 12033-7.
120. D'Costa, S.M., T.W. Bainbridge, and R.C. Condit, Purification and properties
of the vaccinia virus mRNA processing factor. J Biol Chem, 2007.
121. Pennington, T.H. and E.A. Follett, Vaccinia virus replication in enucleate
BSC-1 cells: particle production and synthesis of viral DNA and proteins. J
Virol, 1974. 13(2): p. 488-93.
122. Prescott, D.M., J. Kates, and J.B. Kirkpatrick, Replication of vaccinia virus
DNA in enucleated L-cells. J Mol Biol, 1971. 59(3): p. 505-8.
123. Challberg, M.D. and P.T. Englund, Purification and properties of the
deoxyribonucleic acid polymerase induced by vaccinia virus. J Biol Chem,
1979. 254(16): p. 7812-9.
124. Upton, C., D.T. Stuart, and G. McFadden, Identification of a poxvirus gene
encoding a uracil DNA glycosylase. Proc Natl Acad Sci U S A, 1993. 90(10):
p. 4518-22.
125. Traktman, P., M.K. Anderson, and R.E. Rempel, Vaccinia virus encodes an
essential gene with strong homology to protein kinases. J Biol Chem, 1989.
264(36): p. 21458-61.
126. Rempel, R.E. and P. Traktman, Vaccinia virus B1 kinase: phenotypic analysis
of temperature-sensitive mutants and enzymatic characterization of
recombinant proteins. J Virol, 1992. 66(7): p. 4413-26.
127. Evans, E. and P. Traktman, Characterization of vaccinia virus DNA
replication mutants with lesions in the D5 gene. Chromosoma, 1992. 102(1
Suppl): p. S72-82.
128. Evans, E., et al., The vaccinia virus D5 protein, which is required for DNA
replication, is a nucleic acid-independent nucleoside triphosphatase. J Virol,
1995. 69(9): p. 5353-61.
129. Ishii, K. and B. Moss, Role of vaccinia virus A20R protein in DNA
replication: construction and characterization of temperature-sensitive
mutants. J Virol, 2001. 75(4): p. 1656-63.
130. Nichols, R.J., M.S. Wiebe, and P. Traktman, The vaccinia-related kinases
phosphorylate the N' terminus of BAF, regulating its interaction with DNA
and its retention in the nucleus. Mol Biol Cell, 2006. 17(5): p. 2451-64.
131. Wiebe, M.S. and P. Traktman, Poxviral B1 kinase overcomes barrier to
autointegration factor, a host defense against virus replication. Cell Host
Microbe, 2007. 1(3): p. 187-97.
110
132. Iyer, L.M., et al., Origin and evolution of the archaeo-eukaryotic primase
superfamily and related palm-domain proteins: structural insights and new
members. Nucleic Acids Res, 2005. 33(12): p. 3875-96.
133. De Silva, F.S., et al., Poxvirus DNA primase. Proc Natl Acad Sci U S A, 2007.
104(47): p. 18724-9.
134. Stanitsa, E.S., L. Arps, and P. Traktman, Vaccinia virus uracil DNA
glycosylase interacts with the A20 protein to form a heterodimeric
processivity factor for the viral DNA polymerase. J Biol Chem, 2006. 281(6):
p. 3439-51.
135. DeLange, A.M. and G. McFadden, Sequence-nonspecific replication of
transfected plasmid DNA in poxvirus-infected cells. Proc Natl Acad Sci U S
A, 1986. 83(3): p. 614-8.
136. De Silva, F.S. and B. Moss, Origin-independent plasmid replication occurs in
vaccinia virus cytoplasmic factories and requires all five known poxvirus
replication factors. Virol J, 2005. 2: p. 23.
137. Merchlinsky, M., Mutational analysis of the resolution sequence of vaccinia
virus DNA: essential sequence consists of two separate AT-rich regions highly
conserved among poxviruses. J Virol, 1990. 64(10): p. 5029-35.
138. Merchlinsky, M. and B. Moss, Resolution of vaccinia virus DNA concatemer
junctions requires late-gene expression. J Virol, 1989. 63(4): p. 1595-603.
139. Garcia, A.D., et al., Bacterial-type DNA holliday junction resolvases in
eukaryotic viruses. Proc Natl Acad Sci U S A, 2000. 97(16): p. 8926-31.
140. Garcia, A.D. and B. Moss, Repression of vaccinia virus Holliday junction
resolvase inhibits processing of viral DNA into unit-length genomes. J Virol,
2001. 75(14): p. 6460-71.
141. Husain, M., A.S. Weisberg, and B. Moss, Existence of an operative pathway
from the endoplasmic reticulum to the immature poxvirus membrane. Proc
Natl Acad Sci U S A, 2006. 103(51): p. 19506-11.
142. Betakova, T., E.J. Wolffe, and B. Moss, Regulation of vaccinia virus
morphogenesis: phosphorylation of the A14L and A17L membrane proteins
and C-terminal truncation of the A17L protein are dependent on the F10L
kinase. J Virol, 1999. 73(5): p. 3534-43.
143. Resch, W., A.S. Weisberg, and B. Moss, Vaccinia virus nonstructural protein
encoded by the A11R gene is required for formation of the virion membrane.
Journal of Virology, 2005. 79(11): p. 6598-6609.
144. DeMasi, J. and P. Traktman, Clustered charge-to-alanine mutagenesis of the
vaccinia virus H5 gene: isolation of a dominant, temperature-sensitive mutant
with a profound defect in morphogenesis. J Virol, 2000. 74(5): p. 2393-405.
145. Szajner, P., et al., A complex of seven vaccinia virus proteins conserved in all
chordopoxviruses is required for the association of membranes and viroplasm
to form immature virions. Virology, 2004. 330(2): p. 447-59.
146. Baldick, C.J., Jr. and B. Moss, Resistance of vaccinia virus to rifampicin
conferred by a single nucleotide substitution near the predicted NH2 terminus
of a gene encoding an Mr 62,000 polypeptide. Virology, 1987. 156(1): p. 138-
45.
111
147. Szajner, P., et al., External scaffold of spherical immature poxvirus particles
is made of protein trimers, forming a honeycomb lattice. J Cell Biol, 2005.
170(6): p. 971-81.
148. Cassetti, M.C., et al., DNA packaging mutant: repression of the vaccinia virus
A32 gene results in noninfectious, DNA-deficient, spherical, enveloped
particles. J Virol, 1998. 72(7): p. 5769-80.
149. Grubisha, O. and P. Traktman, Genetic analysis of the vaccinia virus 16
telomere-binding protein uncovers a key role in genome encapsidation.
Journal of Virology, 2003. 77(20): p. 10929-10942.
150. Ansarah-Sobrinho, C. and B. Moss, Vaccinia virus G1 protein, a predicted
metalloprotease, is essential for morphogenesis of infectious virions but not
for cleavage of major core proteins. J Virol, 2004. 78(13): p. 6855-63.
151. Ansarah-Sobrinho, C. and B. Moss, Role of the I7 protein in proteolytic
processing of vaccinia virus membrane and core components. J Virol, 2004.
78(12): p. 6335-43.
152. Blasco, R. and B. Moss, Extracellular vaccinia virus formation and cell-to-
cell virus transmission are prevented by deletion of the gene encoding the
37,000-Dalton outer envelope protein. J Virol, 1991. 65(11): p. 5910-20.
153. Engelstad, M., S.T. Howard, and G.L. Smith, A constitutively expressed
vaccinia gene encodes a 42-kDa glycoprotein related to complement control
factors that forms part of the extracellular virus envelope. Virology, 1992.
188(2): p. 801-10.
154. Wolffe, E.J., S.N. Isaacs, and B. Moss, Deletion of the vaccinia virus B5R
gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular
virus envelope formation and dissemination. J Virol, 1993. 67(8): p. 4732-41.
155. Sanderson, C.M., M. Hollinshead, and G.L. Smith, The vaccinia virus A27L
protein is needed for the microtubule-dependent transport of intracellular
mature virus particles. Journal of General Virology, 2000. 81(1): p. 47-58.
156. Hollinshead, M., et al., Vaccinia virus utilizes microtubules for movement to
the cell surface. J Cell Biol, 2001. 154(2): p. 389-402.
157. Ward, B.M. and B. Moss, Vaccinia virus intracellular movement is associated
with microtubules and independent of actin tails. J Virol, 2001. 75(23): p.
11651-63.
158. Ward, B.M. and B. Moss, Vaccinia virus A36R membrane protein provides a
direct link between intracellular enveloped virions and the microtubule motor
kinesin. J Virol, 2004. 78(5): p. 2486-93.
159. Herrero-Martinez, E., et al., Vaccinia virus intracellular enveloped virions
move to the cell periphery on microtubules in the absence of the A36R protein.
J Gen Virol, 2005. 86(Pt 11): p. 2961-8.
160. Cudmore, S., et al., Actin-based motility of vaccinia virus. Nature, 1995.
378(6557): p. 636-8.
161. Wolffe, E.J., A.S. Weisberg, and B. Moss, Role for the vaccinia virus A36R
outer envelope protein in the formation of virus-tipped actin-containing
microvilli and cell-to-cell virus spread. Virology, 1998. 244(1): p. 20-6.
112
162. Roper, R.L., et al., The envelope protein encoded by the A33R gene is
required for formation of actin-containing microvilli and efficient cell-to-cell
spread of vaccinia virus. J Virol, 1998. 72(5): p. 4192-204.
163. Wolffe, E.J., et al., The A34R glycoprotein gene is required for induction of
specialized actin-containing microvilli and efficient cell-to-cell transmission
of vaccinia virus. J Virol, 1997. 71(5): p. 3904-15.
164. Frischknecht, F., et al., Actin-based motility of vaccinia virus mimics receptor
tyrosine kinase signalling. Nature, 1999. 401(6756): p. 926-9.
165. Doms, R.W., R. Blumenthal, and B. Moss, Fusion of intra- and extracellular
forms of vaccinia virus with the cell membrane. J Virol, 1990. 64(10): p.
4884-92.
166. Gong, S.C., C.F. Lai, and M. Esteban, Vaccinia virus induces cell fusion at
acid pH and this activity is mediated by the N-terminus of the 14-kDa virus
envelope protein. Virology, 1990. 178(1): p. 81-91.
167. Ichihashi, Y. and S. Dales, Biogenesis of poxviruses: interrelationship
between hemagglutinin production and polykaryocytosis. Virology, 1971.
46(3): p. 533-43.
168. Law, K.M. and G.L. Smith, A vaccinia serine protease inhibitor which
prevents virus-induced cell fusion. J Gen Virol, 1992. 73 ( Pt 3): p. 549-57.
169. Turner, P.C. and R.W. Moyer, An orthopoxvirus serpin-like gene controls the
ability of infected cells to fuse. J. Virol., 1992. 66: p. 2076-2085.
170. Zhou, J., et al., The vaccinia virus K2L gene encodes a serine protease
inhibitor which inhibits cell-cell fusion. Virology, 1992. 189(2): p. 678-86.
171. Smith, G.L., S.T. Howard, and Y.S. Chan, Vaccinia virus encodes a family of
genes with homology to serine proteinase inhibitors. J Gen Virol, 1989. 70 (
Pt 9): p. 2333-43.
172. Seki, M., et al., Hemadsorption and fusion inhibition activities of
hemagglutinin analyzed by vaccinia virus mutants. Virology, 1990. 175: p.
372-384.
173. Turner, P.C. and R.W. Moyer, The cowpox virus fusion regulator proteins
SPI-3 and hemagglutinin interact in infected and uninfected cells. Virology,
2006. 347(1): p. 88-99.
174. Brum, L.M., et al., Plasma membrane localization and fusion inhibitory
activity of the cowpox virus serpin SPI-3 require a functional signal sequence
and the virus encoded hemagglutinin. Virology, 2003. 306(2): p. 289-302.
175. Shida, H. and S. Dales, Biogenesis of vaccinia: Carbohydrate of the
hemagglutinin molecule. Virology, 1981. 111: p. 56-72.
176. Krauss, O., et al., An investigation of incorporation of cellular antigens into
vaccinia virus particles. J Gen Virol, 2002. 83(Pt 10): p. 2347-59.
177. Lee, M.S., et al., Molecular attenuation of vaccinia virus: mutant generation
and animal characterization. J Virol, 1992. 66(5): p. 2617-30.
178. Turner, P.C., et al., The cowpox virus serpin SPI-3 complexes with and
inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Virology, 2000. 272(2): p. 267-280.
113
179. Wang, Y.X., et al., The cowpox virus SPI-3 and myxoma virus SERP1 serpins
are not functionally interchangeable despite their similar proteinase
inhibition profiles in vitro. Virology, 2000. 272(2): p. 281-292.
180. Turner, P.C. and R.W. Moyer, Orthpoxvirus fusion inhibitor glycoprotein
SPI-3 (open reading frame K2L) contains motifs characteristic of serine
protease inhibitors that are not required for control of cell fusion. J. Virol.,
1995. 69: p. 5978-5987.
181. Husain, M., A.S. Weisberg, and B. Moss, Resistance of a vaccinia virus A34R
deletion mutant to spontaneous rupture of the outer membrane of progeny
virions on the surface of infected cells. Virology, 2007. 366(2): p. 424-32.
182. Condit, R.C., N. Moussatche, and P. Traktman, In a nutshell: structure and
assembly of the vaccinia virion. Adv Virus Res, 2006. 66: p. 31-124.
183. Smith, G.L. and M. Law, The exit of vaccinia virus from infected cells. Virus
Res, 2004. 106(2): p. 189-97.
184. Payne, L.G., Identification of the vaccinia hemagglutinin polypeptide from a
cell system yielding large amounts of extracellular enveloped virus. J Virol,
1979. 31(1): p. 147-55.
185. Wagenaar, T.R. and B. Moss, Association of vaccinia virus fusion regulatory
proteins with the multicomponent entry/fusion complex. J Virol, 2007. 81(12):
p. 6286-93.
186. Earl, P.L., et al., Preparation of cell cultures and vaccinia virus stocks, in
Current Protocols in Molecular Biology, F.M. Ausubel, et al., Editors. 1998,
John Wiley and Sons: New York. p. 16.16.1-16.16.3.
187. Ward, G.A., et al., Stringent chemical and thermal regulation of recombinant
gene expression by vaccinia virus vectors in mammalian cells. Proc Natl Acad
Sci U S A, 1995. 92(15): p. 6773-7.
188. Blasco, R. and B. Moss, Selection of recombinant vaccinia viruses on the
basis of plaque formation. Gene, 1995. 158(2): p. 157-62.
189. DeMasi, J., et al., Vaccinia virus telomeres: interaction with the viral I1, I6,
and K4 proteins. J Virol, 2001. 75(21): p. 10090-105.
190. Klemperer, N., et al., The vaccinia virus I1 protein is essential for the
assembly of mature virions. J Virol, 1997. 71(12): p. 9285-94.
191. Ahn, B.Y. and B. Moss, Glutaredoxin homolog encoded by vaccinia virus is a
virion-associated enzyme with thioltransferase and dehydroascorbate
reductase activities. Proc Natl Acad Sci U S A, 1992. 89(15): p. 7060-4.
192. Rajagopal, I., et al., Roles of vaccinia virus ribonucleotide reductase and
glutaredoxin in DNA precursor biosynthesis. J Biol Chem, 1995. 270(46): p.
27415-8.
193. Lippincott-Schwartz, J., et al., Rapid redistribution of Golgi proteins in the ER
in cells treated with brefeldin A, evidence for membrane cycling from Golgi to
ER. Cell, 1989. 56: p. 801-813.
194. Doms, R.W., G. Russ, and J.W. Yewdell, Brefeldin A redistributes resident
and itinerant Golgi proteins to the enodplasmic reticulum. J. Cell Biol., 1989.
109: p. 61-72.
195. Ulaeto, D., D. Grosenbach, and D.E. Hruby, Brefeldin A inhibits vaccinia
virus envelopment but does not prevent normal processing and localization of
114
the putative envelopment receptor P37. J Gen Virol, 1995. 76 ( Pt 1): p. 103-
11.
196. Buck, C.B., et al., Efficient intracellular assembly of papillomaviral vectors. J
Virol, 2004. 78(2): p. 751-7.
197. Falkner, F.G. and B. Moss, Transient dominant selection of recombinant
vaccinia viruses. J Virol, 1990. 64(6): p. 3108-11.
198. Blasco, R. and B. Moss, Role of cell-associated enveloped vaccinia virus in
cell-to-cell spread. J Virol, 1992. 66(7): p. 4170-9.
199. Moss, B., Poxvirus entry and membrane fusion. Virology, 2006. 344(1): p. 48-
54.
200. Ruyechan, W.T., et al., Molecular genetics of herpes simplex virus. II.
Mapping of the major viral glycoproteins and of the genetic loci specifying the
social behavior of infected cells. J Virol, 1979. 29(2): p. 677-97.
201. Bzik, D.J., et al., Nucleotide sequence of a region of the herpes simplex virus
type 1 gB glycoprotein gene: mutations affecting rate of virus entry and cell
fusion. Virology, 1984. 137(1): p. 185-90.
202. Baines, J.D., et al., The UL20 gene of herpes simplex virus 1 encodes a
function necessary for viral egress. J Virol, 1991. 65(12): p. 6414-24.
203. Muggeridge, M.I., M.L. Grantham, and F.B. Johnson, Identification of
syncytial mutations in a clinical isolate of herpes simplex virus 2. Virology,
2004. 328(2): p. 244-53.
